151
|
Sugawara T, Sawada D, Yanagihara S, Aoki Y, Takehara I, Sugahara H, Hirota T, Nakamura Y, Ishikawa S. Daily Intake of Paraprobiotic Lactobacillus amylovorus CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study. Microorganisms 2020; 8:microorganisms8020304. [PMID: 32098338 PMCID: PMC7074956 DOI: 10.3390/microorganisms8020304] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Revised: 02/14/2020] [Accepted: 02/20/2020] [Indexed: 12/26/2022] Open
Abstract
Despite the fact that gut microbiota is closely associated with obesity, few studies have focused on the influences of paraprobiotics as food ingredients on both obesity prevention and the gut microbial community. In this study, we evaluated the effects of fragmented Lactobacillus amylovorus CP1563 (CP1563) as a paraprobiotic for obesity prevention and investigated its effects on the gut microbial community in pre-obese subjects. One hundred sixty-nine healthy subjects with a body mass index from 25.0 to 29.9 kg/m2 ingested beverages with or without the fragmented CP1563 containing 10-hydroxyoctadecanoic acid (10-HOA) for 12 weeks. The changes in abdominal, total, visceral, and subcutaneous fatty areas were significantly lower in the CP1563-10-HOA group than in the placebo group at 12 weeks. Furthermore, 16S rRNA gene sequencing of fecal DNA revealed that the changes in the abundances of the genera Roseburia and Lachnospiraceae;g were significantly greater in the CP1563-10-HOA group than in the placebo group, and the changes in the abundances of the genus Collinsella was significantly smaller in the CP1563-10HOA group than in the placebo group. Our results showed that continuous ingestion of the fragmented CP1563 containing 10-HOA reduced abdominal body fat and affected the gut microbial community in pre-obese healthy subjects. Our findings may contribute to the understanding of the relationship between the anti-obesity effect of paraprobiotics and gut microbiota.
Collapse
Affiliation(s)
- Tomonori Sugawara
- Core Technology Laboratories, Asahi Quality and Innovations, Ltd., 11-10, 5 Chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan
- Correspondence: ; Tel.: +81-42-769-7828
| | - Daisuke Sawada
- Core Technology Laboratories, Asahi Quality and Innovations, Ltd., 11-10, 5 Chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan
| | - Sae Yanagihara
- Core Technology Laboratories, Asahi Quality and Innovations, Ltd., 11-10, 5 Chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan
| | - Yumeko Aoki
- Core Technology Laboratories, Asahi Quality and Innovations, Ltd., 11-10, 5 Chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan
| | - Isao Takehara
- PI-Food Service Division, Clinical Support Corporation, 4-1, Nishi 8 Chome, Minami 1 jo, Chuo-ku, Sapporo-shi, Hokkaido 060-0061, Japan
| | - Hirosuke Sugahara
- Core Technology Laboratories, Asahi Quality and Innovations, Ltd., 11-10, 5 Chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan
| | - Tatsuhiko Hirota
- Core Technology Laboratories, Asahi Quality and Innovations, Ltd., 11-10, 5 Chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan
| | - Yasunori Nakamura
- Core Technology Laboratories, Asahi Quality and Innovations, Ltd., 11-10, 5 Chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan
| | - Susumu Ishikawa
- Medical Corporation Shoureikan Sinsapporo Seiryo Hospital, 1-30, 2 Chome, Higashi 4 jo, Atsubetsu, Atsubetsu-ku, Sapporo-shi, Hokkaido 004-0004, Japan
| |
Collapse
|
152
|
Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial. EPMA J 2020; 11:31-51. [PMID: 32140184 DOI: 10.1007/s13167-020-00198-y] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Accepted: 01/09/2020] [Indexed: 02/06/2023]
Abstract
Background Prevention and improvement of disease symptoms are important issues, and probiotics are suggested as a good treatment for controlling the obesity. Human gut microbiota has different community structures. Because gut microbial composition is assumed to be linked to probiotic function, this study evaluated the efficacy of probiotics on obesity-related clinical markers according to gut microbial enterotype. Methods Fifty subjects with body mass index over 25 kg/m2 were randomly assigned to either the probiotic or placebo group. Each group received either unlabeled placebo or probiotic capsules for 12 weeks. Body weight, waist circumference, and body composition were measured every 3 weeks. Using computed tomography, total abdominal fat area and visceral fat area were measured. Blood and fecal samples were collected before and after the intervention for biochemical parameters and gut microbial compositions analysis. Results Gut microbial compositions of all the subjects were classified into two enterotypes according to Prevotella/Bacteroides ratio. The fat percentage, blood glucose, and insulin significantly increased in the Prevotella-rich enterotype of the placebo group. The obesity-related markers, such as waist circumference, total fat area, visceral fat, and ratio of visceral to subcutaneous fat area, were significantly reduced in the probiotic group. The decrease of obesity-related markers was greater in the Prevotella-rich enterotype than in the Bacteroides-rich enterotype. Conclusion Administration of probiotics improved obesity-related markers in obese people, and the efficacy of probiotics differed per gut microbial enterotype and greater responses were observed in the Prevotella-dominant enterotype.
Collapse
|
153
|
Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr 2020; 123:1127-1137. [PMID: 32008579 DOI: 10.1017/s0007114520000380] [Citation(s) in RCA: 184] [Impact Index Per Article: 46.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The global obesity epidemic has necessitated the search for better intervention strategies including the exploitation of the health benefits of some gut microbiota and their metabolic products. Therefore, we examined the gut microbial composition and mechanisms of interaction with the host in relation to homoeostatic energy metabolism and pathophysiology of dysbiosis-induced metabolic inflammation and obesity. We also discussed the eubiotic, health-promoting effects of probiotics and prebiotics as well as epigenetic modifications associated with gut microbial dysbiosis and risk of obesity. High-fat/carbohydrate diet programmes the gut microbiota to one predominated by Firmicutes (Clostridium), Prevotella and Methanobrevibacter but deficient in beneficial genera/species such as Bacteroides, Bifidobacterium, Lactobacillus and Akkermansia. Altered gut microbiota is associated with decreased expression of SCFA that maintain intestinal epithelial barrier integrity, reduce bacterial translocation and inflammation and increase expression of hunger-suppressing hormones. Reduced amounts of beneficial micro-organisms also inhibit fasting-induced adipocyte factor expression leading to dyslipidaemia. A low-grade chronic inflammation (metabolic endotoxaemia) ensues which culminates in obesity and its co-morbidities. The synergy of high-fat diet and dysbiotic gut microbiota initiates a recipe that epigenetically programmes the host for increased adiposity and poor glycaemic control. Interestingly, these obesogenic mechanistic pathways that are transmittable from one generation to another can be modulated through the administration of probiotics, prebiotics and synbiotics. Though the influence of gut microbiota on the risk of obesity and several intervention strategies have been extensively demonstrated in animal models, application in humans still requires further robust investigation.
Collapse
|
154
|
Liu Y, Lou X. Type 2 diabetes mellitus-related environmental factors and the gut microbiota: emerging evidence and challenges. Clinics (Sao Paulo) 2020; 75:e1277. [PMID: 31939557 PMCID: PMC6945290 DOI: 10.6061/clinics/2020/e1277] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 10/04/2019] [Indexed: 01/15/2023] Open
Abstract
The gut microbiota is a group of over 38 trillion bacterial cells in the human microbiota that plays an important role in the regulation of human metabolism through its symbiotic relationship with the host. Changes in the gut microbial ecosystem are associated with increased susceptibility to metabolic disease in humans. However, the composition of the gut microbiota in those with type 2 diabetes mellitus and in the pathogenesis of metabolic diseases is not well understood. This article reviews the relationship between environmental factors and the gut microbiota in individuals with type 2 diabetes mellitus. Finally, we discuss the goal of treating type 2 diabetes mellitus by modifying the gut microbiota and the challenges that remain in this area.
Collapse
Affiliation(s)
- Yanfen Liu
- Jinhua Municipal Central Hospital, Department of Endocrinology Jinhua, 321000, China
| | - Xueyong Lou
- Jinhua Municipal Central Hospital, Department of Endocrinology Jinhua, 321000, China
- *Corresponding author. E-mail:
| |
Collapse
|
155
|
Xavier-Santos D, Bedani R, Lima ED, Saad SMI. Impact of probiotics and prebiotics targeting metabolic syndrome. J Funct Foods 2020. [DOI: 10.1016/j.jff.2019.103666] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
156
|
Yu R, Yin Y, Cao M, Ye D, Zhang Y, Zhou Q, Mei Y. Fructo-oligosaccharides lower serum lipid levels and suppress high-fat/high-sugar diet-induced inflammation by elevating serum and gut levels of short-chain fatty acids. J Int Med Res 2019; 48:300060519896714. [PMID: 31891285 PMCID: PMC7783246 DOI: 10.1177/0300060519896714] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Objective This study aimed to investigate the effects of fructo-oligosaccharides (FOS)
on serum lipid levels and to determine the mechanisms underlying these
effects and the potential role of inflammation. Methods Male C57BL/6 mice received a normal diet, a high-fat/high-sugar (HFS) diet,
or an HFS diet supplemented with 10% FOS for 10 weeks. In
vivo intestinal and serum short-chain fatty acid (SCFA) levels
were measured by gas chromatography. In vivo serum levels
of alanine transaminase (ALT), aspartate aminotransferase (AST), total
cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL),
low-density lipoprotein (LDL), interleukin-6 (IL-6), tumor necrosis factor-α
(TNF-α), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and malonaldehyde (MDA) were
also measured. Lipid accumulation was visualized. Reactive oxygen species
(ROS) generation was evaluated and apoptosis was quantified. Results FOS reversed in vivo HFS-induced lipid accumulation in the
liver. An HFS diet increased ALT, AST, TC, TG, and LDL serum levels,
decreased HDL serum levels, and increased IL-6, TNF-α, 8-OHdG, and MDA
levels. These changes were reduced by FOS. FOS also increased intestinal and
serum levels of short chain fatty acids (SCFAs). In vitro,
SCFAs ameliorated palmitic acid-induced ROS production and apoptosis of
HepG2 cells. Conclusion FOS supplementation lowers serum lipid levels and ameliorates HFS-induced
inflammation by upregulating SCFAs.
Collapse
Affiliation(s)
- Renqiang Yu
- Department of Neonatology, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China
| | - Yongxiang Yin
- Department of Pathology, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China
| | - Minkai Cao
- Department of Gynaecology and Obstetrics, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China
| | - Danni Ye
- Department of Neonatology, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China
| | - Yinghui Zhang
- Department of Neonatology, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China
| | - Qin Zhou
- Department of Neonatology, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China
| | - Yingzi Mei
- Department of Neonatology, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China
| |
Collapse
|
157
|
Kim B, Choi HN, Yim JE. Effect of Diet on the Gut Microbiota Associated with Obesity. J Obes Metab Syndr 2019; 28:216-224. [PMID: 31909364 PMCID: PMC6939700 DOI: 10.7570/jomes.2019.28.4.216] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 08/24/2019] [Accepted: 11/13/2019] [Indexed: 02/06/2023] Open
Abstract
Obesity is abnormal or excessive fat accumulation that is associated with progression of metabolic diseases including type 2 diabetes mellitus, cardiovascular disease, nonalcoholic fatty liver disease, and cancer. Gut microbiota (GM) have received much attention as essential factors in development and progression of obesity. The diversity, composition, and metabolic activity of GM are closely associated with nutrient intake and dietary pattern. Scientific evidence supports the idea that dietary pattern directly changes the GM profile; therefore, diet is a crucial component related to interactions between GM and obesity progression. A literature review showed that dietary factors such as probiotics, prebiotics, fat, fatty acids, and fiber dramatically alter the GM profile related to obesity. Furthermore, different dietary patterns result in different GM composition and activity that can contribute to amelioration of obesity.
Collapse
Affiliation(s)
- Bohkyung Kim
- Department of Food Science and Nutrition, Pusan National University, Busan, Korea
| | - Ha-Neul Choi
- Department of Food and Nutrition, Changwon National University, Changwon, Korea
| | - Jung-Eun Yim
- Department of Food and Nutrition, Changwon National University, Changwon, Korea
| |
Collapse
|
158
|
Louis-Jean S, Martirosyan D. Nutritionally Attenuating the Human Gut Microbiome To Prevent and Manage Metabolic Syndrome. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2019; 67:12675-12684. [PMID: 31661963 DOI: 10.1021/acs.jafc.9b04879] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Metabolic syndrome (MSyn) constitutes a litany of pathophysiological conditions, such as central adiposity, hypertension, dyslipidemia, and hyperglycemia. As a result of the epidemic levels of MSyn, several efforts have been made to identify the etiologies of the condition and develop methods by which to reduce its prevalence. The attenuation of the gut microflora ratio of Firmicutes/Bacteroidetes through bioactive compounds found in the Mediterranean diet, dietary polysaccharides, and pre- and probiotics can be used as functional foods to improve derangements in cardiometabolic markers correlated with the development of MSyn. Although more studies are needed to understand the role of manipulating the gut microbiota in health and disease in human models, this review based on current data from epidemiologic studies and clinical trials will serve as a review to elucidate the role nutrition plays in attenuating the gut microbiota in preventing and managing MSyn.
Collapse
Affiliation(s)
- Scarlet Louis-Jean
- Functional Food Center , Functional Food Institute , Dallas , Texas 75254 , United States
| | - Danik Martirosyan
- Functional Food Center , Functional Food Institute , Dallas , Texas 75254 , United States
| |
Collapse
|
159
|
Gut Microbiota and Obesity: A Role for Probiotics. Nutrients 2019; 11:nu11112690. [PMID: 31703257 PMCID: PMC6893459 DOI: 10.3390/nu11112690] [Citation(s) in RCA: 318] [Impact Index Per Article: 63.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2019] [Revised: 09/23/2019] [Accepted: 09/24/2019] [Indexed: 02/07/2023] Open
Abstract
Nowadays, obesity is one of the most prevalent human health problems. Research from the last 30 years has clarified the role of the imbalance between energy intake and expenditure, unhealthy lifestyle, and genetic variability in the development of obesity. More recently, the composition and metabolic functions of gut microbiota have been proposed as being able to affect obesity development. Here, we will report the current knowledge on the definition, composition, and functions of intestinal microbiota. We have performed an extensive review of the literature, searching for the following keywords: metabolism, gut microbiota, dysbiosis, obesity. There is evidence for the association between gut bacteria and obesity both in infancy and in adults. There are several genetic, metabolic, and inflammatory pathophysiological mechanisms involved in the interplay between gut microbes and obesity. Microbial changes in the human gut can be considered a factor involved in obesity development in humans. The modulation of the bacterial strains in the digestive tract can help to reshape the metabolic profile in the human obese host as suggested by several data from animal and human studies. Thus, a deep revision of the evidence pertaining to the use probiotics, prebiotics, and antibiotics in obese patients is conceivable
Collapse
|
160
|
Wang T, Yan H, Lu Y, Li X, Wang X, Shan Y, Yi Y, Liu B, Zhou Y, Lü X. Anti-obesity effect of Lactobacillus rhamnosus LS-8 and Lactobacillus crustorum MN047 on high-fat and high-fructose diet mice base on inflammatory response alleviation and gut microbiota regulation. Eur J Nutr 2019; 59:2709-2728. [PMID: 31659451 DOI: 10.1007/s00394-019-02117-y] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 10/11/2019] [Indexed: 02/07/2023]
Abstract
PURPOSE The objective of the study was to evaluate the anti-obesity effect of Lactobacillus rhamnosus LS-8 and Lactobacillus crustorum MN047, and illustrate the potential functional mechanism about the alleviation of high fat and high fructose diet (HFFD) induced obesity and related metabolic abnormalities. METHODS C57BL/6J mice were subjected to a standard or HFFD with or without supplementation of L. rhamnosus LS-8 and L. crustorum MN047 for 10 weeks. Obesity related metabolic indices including glucose tolerance, insulin resistance, serum lipid, liver function, hormones and inflammatory cytokines were assessed by standard protocols. For the monitoring of inflammatory response and lipid metabolism, transcriptional levels were profiled in liver and/or adipose tissues. Furthermore, gut microbiota composition analyses in the fecal samples were performed using 16S rRNA gene sequencing, and gut microbial metabolites, including lipopolysaccharide (LPS) and short-chain fatty acids (SCFAs), were also tested for the assessment of the relationship between gut microbiota variation and inflammatory response. RESULTS Administration with L. rhamnosus LS-8 and L. crustorum MN047 significantly mitigated body weight gain and insulin resistance, and inflammatory response (TNF-α, IL-1β and IL-6 levels in serum and corresponding mRNA levels in adipose tissues) was significantly inhibited in these two strains-treated mice. Moreover, L. rhamnosus LS-8 and L. crustorum MN047 could partially normalized mRNA expression levels involved in lipid metabolism including Pparγ, Srebp-1c, CD36, Fabp2 and FAS. In addition, these two strains manipulated gut microbiota by decreasing the abundance of Bacteroides and Desulfovibrio and increasing that of Lactobacillus and Bifidobacterium, which in turn raised the levels of feces SCFAs and lowered the levels of circulating LPS. CONCLUSION These results indicated that L. rhamnosus LS-8 and L. crustorum MN047 supplementation possessed the anti-obesity effect on the HFFD fed mice by alleviating inflammatory response and regulating gut microbiota, which further suggested that these two probiotics can be considered as an alternative dietary supplement in combination with the preventive and therapeutic strategies against obesity and related complications.
Collapse
Affiliation(s)
- Tao Wang
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Hong Yan
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Yingying Lu
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Xin Li
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Xin Wang
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Yuanyuan Shan
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Yanglei Yi
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Bianfang Liu
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Yuan Zhou
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China
| | - Xin Lü
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China.
| |
Collapse
|
161
|
Liu Q, Liu Y, Li F, Gu Z, Liu M, Shao T, Zhang L, Zhou G, Pan C, He L, Cai J, Zhang X, Barve S, McClain CJ, Chen Y, Feng W. Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. J Nutr Biochem 2019; 75:108256. [PMID: 31760308 DOI: 10.1016/j.jnutbio.2019.108256] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 08/01/2019] [Accepted: 10/01/2019] [Indexed: 02/07/2023]
Abstract
High-fat/high-fructose diet plus intermittent hypoxia exposure (HFDIH) causes metabolic disorders such as insulin resistance, obesity, nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. The purpose of this study is to examine the effects and understand the mechanism of action of Lactobacillus rhamnosus GG culture supernatant (LGGs) on HFDIH-induced metabolic dysfunction. Mice were fed high-fat:high-fructose diet for 15 weeks. After 3 weeks of feeding, the mice were exposed to chronic intermittent hypoxia for the next 12 weeks (HFDIH), and LGGs was supplemented over the entire experiment. HFDIH exposure significantly led to metabolic disorders. LGGs treatment showed significant improvements in indices of metabolic disorders including fat mass, energy expenditure, glucose intolerance, insulin resistance, increased hepatic steatosis and liver injury. HFDIH mice markedly increased adipose inflammation and adipocyte size, and reduced circulating adiponectin, which was restored by LGGs treatment. LGGs treatment increased hepatic FGF21 mRNA expression and circulating FGF21 protein levels, which were associated with increased hepatic PPARα expression and fecal butyrate concentration. In addition, HFDIH-induced hepatic fat accumulation and apoptosis were significantly reduced by LGGs supplementation. In summary, LGGs treatment increased energy expenditure and insulin sensitivity and prevented metabolic abnormalities in HFDIH mice, and this is associated with the FGF21-adiponectin signaling pathway. LGGs may be a potential prevention/treatment strategy in subjects with the metabolic syndrome.
Collapse
Affiliation(s)
- Qi Liu
- Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA
| | - Yunhuan Liu
- Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA
| | - Fengyuan Li
- Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Zelin Gu
- Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA
| | - Min Liu
- School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA
| | - Tuo Shao
- Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA
| | - Lihua Zhang
- Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA
| | - Guangyao Zhou
- Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA
| | - Chengwei Pan
- Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Liqing He
- Department of Chemistry, University of Louisville, Louisville, KY, USA
| | - Jun Cai
- Department of Pediatrics, University of Louisville, Louisville, KY, USA
| | - Xiang Zhang
- Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA; Department of Chemistry, University of Louisville, Louisville, KY, USA
| | - Shirish Barve
- Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Craig J McClain
- Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA; Robley Rex VA medical Center, Louisville, KY, USA
| | - Yiping Chen
- Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
| | - Wenke Feng
- Department of Medicine, University of Louisville, Louisville, KY, USA; Alcohol Research Center, University of Louisville, Louisville, KY, USA; Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA.
| |
Collapse
|
162
|
Zhai Q, Zhang Q, Tian F, Zhao J, Zhang H, Chen W. The synergistic effect of Lactobacillus plantarum CCFM242 and zinc on ulcerative colitis through modulating intestinal homeostasis. Food Funct 2019; 10:6147-6156. [PMID: 31498347 DOI: 10.1039/c9fo00926d] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The beneficial effects of the essential metal zinc (Zn) and probiotics on gut health have been well documented, but how they synergistically affect intestinal physiology is not thoroughly understood. In this study, the Zn-enriching ability of 33 probiotics in a medium or an aqueous solution was evaluated. A Lactobacillus plantarum strain, CCFM242, with a superior Zn-enriching ability was screened. Among the cellular components, the cell wall played the most important role in the Zn binding of L. plantarum CCFM242. The carboxyl and amino groups on the surface of the strain were also vital for Zn enrichment. Upon optimization of the Zn-enriching procedure, the Zn-binding ability of this strain reached 24.89 ± 0.50 mg g-1 dry biomass. Compared to the treatment of ZnSO4 or L. plantarum CCFM242, oral supplementation with Zn-enriched L. plantarum CCFM242 resulted in a higher serum Zn level, enhanced levels of mRNA expression of colonic tight junctions, increased levels of short-chain fatty acids (SCFAs) in colonic contents, and stronger modulatory effects on the anti-oxidant and immune defense systems in the gut of normal mice. Zn-Enriched L. plantarum CCFM242 treatment also offered more significant protective effects against dextran sodium sulfate (DSS)-induced colitis in mice compared to the treatment of ZnSO4 or L. plantarum CCFM242 alone. The synergistic effect of Zn-enriched L. plantarum CCFM242 may be due to the increased tolerance of the strain to the gastrointestinal tract conditions and the higher bioavailability of Zn after the metal-enrichment process.
Collapse
Affiliation(s)
- Qixiao Zhai
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China. and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China and International Joint Research Laboratory for Probiotics at Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Qingsong Zhang
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China. and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Fengwei Tian
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China. and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Jianxin Zhao
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China. and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Hao Zhang
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China. and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China and National Engineering Research Centre for Functional Food, Wuxi, Jiangsu 214122, China and Wuxi Translational Medicine Research Center and Jiangsu Translational Medicine Research Institute Wuxi Branch, China and (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou 225004, China
| | - Wei Chen
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China. and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China and National Engineering Research Centre for Functional Food, Wuxi, Jiangsu 214122, China and Beijing Innovation Centre of Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing 100048, China
| |
Collapse
|
163
|
Pedret A, Valls RM, Calderón-Pérez L, Llauradó E, Companys J, Pla-Pagà L, Moragas A, Martín-Luján F, Ortega Y, Giralt M, Caimari A, Chenoll E, Genovés S, Martorell P, Codoñer FM, Ramón D, Arola L, Solà R. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond) 2019; 43:1863-1868. [PMID: 30262813 PMCID: PMC6760601 DOI: 10.1038/s41366-018-0220-0] [Citation(s) in RCA: 97] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Revised: 07/25/2018] [Accepted: 08/29/2018] [Indexed: 02/07/2023]
Abstract
BACKGROUND The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-killed form (h-k Ba8145) on human anthropometric adiposity biomarkers are unknown. OBJECTIVE To assess the effect of Ba8145 and h-k Ba8145 ingestion on anthropometric adiposity biomarkers. DESIGN Randomized, parallel, double-blind, placebo-controlled trial with abdominally obese individuals. Participants (n = 135) consumed 1 capsule/day containing 1010 colony forming unit (CFU) of Ba8145, 1010 CFU of h-k Ba8145, or placebo (maltodextrin) for 3 months. RESULTS Ba8145 ingestion decreased waist circumference, waist circumference/height ratio, and Conicity index (P < 0.05) versus its baseline. Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment. Ba8145 decreased the body mass index compared with baseline and placebo group (P < 0.05). The decrease in visceral fat area after Ba8145 treatments reached significance (P < 0.05) only after h-k Ba8145. When analyses by gender were performed, significance remained only for women. Diastolic blood pressure and HOMA index decreased (P < 0.05) after h-k Ba8145. Gut microbiome analyses showed an increase in Akkermansia spp. after Ba8145 treatment, particularly in the live form, which was inversely related to weight (P = 0.003). CONCLUSIONS In abdominally obese individuals, consumption of Ba8145, both as viable and mainly as heat-killed cells, improves anthropometric adiposity biomarkers, particularly in women. An increase in the gut Akkermansia genus appears as a possible mechanism involved. Our results support Ba8145 probiotic as a complementary strategy in obesity management.
Collapse
Affiliation(s)
- Anna Pedret
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain
| | - Rosa M Valls
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.
| | - Lorena Calderón-Pérez
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain
| | - Elisabet Llauradó
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain
| | - Judit Companys
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain
| | - Laura Pla-Pagà
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain
| | - Ana Moragas
- Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain
- Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain
- Primary Care Centre Jaume I, Institut Català de la Salut, Tarragona, Spain
| | - Francisco Martín-Luján
- Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain
- Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain
- Primary Care Centre El Morell, Institut Català de la Salut, Tarragona, Spain
| | - Yolanda Ortega
- Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain
- Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain
- Primary Care Centre Salou, Institut Català de la Salut, Tarragona, Spain
| | - Montse Giralt
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain
| | - Antoni Caimari
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
| | - Empar Chenoll
- Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain
| | - Salvador Genovés
- Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain
| | - Patricia Martorell
- Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain
| | - Francisco M Codoñer
- Lifesequencing/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain
| | - Daniel Ramón
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain
| | - Lluís Arola
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Química, Grup de Recerca en Nutrigenòmica, Tarragona, Spain
| | - Rosa Solà
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain
- Hospital Universitari Sant Joan de Reus, Reus, Spain
| |
Collapse
|
164
|
Jang HR, Park HJ, Kang D, Chung H, Nam MH, Lee Y, Park JH, Lee HY. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. Exp Mol Med 2019; 51:1-14. [PMID: 31409765 PMCID: PMC6802638 DOI: 10.1038/s12276-019-0293-4] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 03/29/2019] [Accepted: 04/16/2019] [Indexed: 12/12/2022] Open
Abstract
The gut microbiome has been known to contribute up to ~30% of the energy absorption of the host. Although various beneficial mechanisms of probiotics have been suggested for non-alcoholic fatty liver disease (NAFLD), whether and which probiotics impact the host's intestinal energy absorption have not yet been quantitatively studied. Here, we suggest a novel mechanism of probiotics against NAFLD, in which Lactobacillus rhamnosus GG, the most common probiotic, shares intestinal fatty acids and prevents the development of diet-induced hepatic steatosis. By using quantitative methods (radioactive tracers and LC-MS) under both in vitro and in vivo conditions, we found that bacteria and hosts competed for fatty acid absorption in the intestine, resulting in decreased weight gain, body fat mass, and hepatic lipid accumulation without differences in calorie intake and excretion in mice fed the probiotic bacteria.
Collapse
Affiliation(s)
- Hye Rim Jang
- Laboratory of Mitochondrial and Metabolic Diseases, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Korea
| | - Hyun-Jun Park
- Laboratory of Mitochondrial and Metabolic Diseases, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Korea
- Department of Medicine, Gachon University School of Medicine, Incheon, Korea
| | - Dongwon Kang
- Laboratory of Mitochondrial and Metabolic Diseases, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Korea
| | - Hayung Chung
- Seoul Center, Korea Basic Science Institute, Seoul, Korea
| | - Myung Hee Nam
- Seoul Center, Korea Basic Science Institute, Seoul, Korea
| | - Yeonhee Lee
- Culture Collection of Antimicrobial Resistant Microbes, Department of Horticulture, Biotechnology and Landscape Architecture, Seoul Women's University, Seoul, Korea
| | - Jae-Hak Park
- Korea Mouse Metabolic Phenotyping Center, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.
| | - Hui-Young Lee
- Laboratory of Mitochondrial and Metabolic Diseases, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Korea.
- Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Korea.
| |
Collapse
|
165
|
Wa Y, Yin B, He Y, Xi W, Huang Y, Wang C, Guo F, Gu R. Effects of Single Probiotic- and Combined Probiotic-Fermented Milk on Lipid Metabolism in Hyperlipidemic Rats. Front Microbiol 2019; 10:1312. [PMID: 31249562 PMCID: PMC6582448 DOI: 10.3389/fmicb.2019.01312] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 05/27/2019] [Indexed: 01/14/2023] Open
Abstract
Previous studies have shown that probiotics have positive effects on hyperlipidemia by lowering the serum lipid concentration and improving the lipid profile. To explore the mechanism by which probiotic-fermented milk improves lipid metabolism, the transcription of genes regulated by liver X receptors (LXRs), 5′-AMP-activated protein kinase, and the farnesoid X receptor (FXR), which play integral roles in lipid metabolism, was investigated in hyperlipidemic rats. Compared with rats fed a high-fat diet, the administration of probiotic-fermented milk significantly lowered the levels of total cholesterol (TC) and total triglycerides (TG) in rat serum and viscera (P < 0.05) and significantly increased the level of total bile acid in the rat liver and small intestine (P < 0.05). The quantitative PCR results showed that the probiotics ameliorated the TC levels in the rats by activating the transcription of genes involved in the LXR axis, which promoted TC reverse transport and increased the conversion of TC to bile acids. The level of TG in the hyperlipidemic rats was ameliorated by the inhibition of the transcription of carbohydrate reaction element binding protein genes and activation of the transcription of PPARα genes. The regulation of lipid metabolism-related gene transcription by the single probiotic (Lactobacillus rhamnosus LV108)-fermented milk was more effective than that by the combined probiotic (L. rhamnosus LV108, Lactobacillus casei grx12, and Lactobacillus fermentum grx08)-fermented milk (P < 0.05).
Collapse
Affiliation(s)
- Yunchao Wa
- Jiangsu Key Laboratory of Dairy Biotechnology and Safety Control, Yangzhou University, Yangzhou, China.,College of Animal Science and Technology, Yangzhou University, Yangzhou, China
| | - Boxing Yin
- Jiangsu Key Laboratory of Dairy Biotechnology and Safety Control, Yangzhou University, Yangzhou, China.,College of Animal Science and Technology, Yangzhou University, Yangzhou, China
| | - Yong He
- Uni-President China Holdings Ltd., Shanghai, China
| | - Wenbo Xi
- Uni-President China Holdings Ltd., Shanghai, China
| | | | - Chunlei Wang
- Uni-President China Holdings Ltd., Shanghai, China
| | - Feixiang Guo
- Uni-President China Holdings Ltd., Shanghai, China
| | - Ruixia Gu
- Jiangsu Key Laboratory of Dairy Biotechnology and Safety Control, Yangzhou University, Yangzhou, China.,College of Food Science and Engineering, Yangzhou University, Yangzhou, China
| |
Collapse
|
166
|
Abstract
PURPOSE OF REVIEW Obesity is a state of chronic inflammation. This review aims to summarize recent data supporting the role of the intestinal mucosal barrier and the microbiome in causing adipose tissue inflammation as well as metabolic factors that can affect the intestinal barrier. RECENT FINDINGS Obesity and its metabolic consequences, such as diabetes mellitus, are associated with disruption of the intestinal barrier function. Intestinal microbiota and diet play a key role in the maintenance of a healthy intestinal epithelium. Intestinal barrier dysfunction can lead to heightened inflammation, which in turn can further damage the intestinal barrier through the disruption of tight junction proteins. Intestinal barrier breakdown is associated with adipose tissue inflammation in different disease states, such as obesity, diabetes mellitus, HIV, and inflammatory bowel disease. Future therapeutic strategies to ameliorate intestinal barrier function may help reduce inflammation in obesity and other chronic conditions of increased intestinal permeability.
Collapse
Affiliation(s)
- Lediya Cheru
- Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, LON-207, Boston, MA, 02114, USA
| | - Charles F Saylor
- Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, LON-207, Boston, MA, 02114, USA
| | - Janet Lo
- Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, LON-207, Boston, MA, 02114, USA.
| |
Collapse
|
167
|
Khodaii Z, Afrasiabi S, Hashemi SA, Ardeshirylajimi A, Natanzi MM. Accelerated wound healing process in rat by probiotic Lactobacillus reuteri derived ointment. J Basic Clin Physiol Pharmacol 2019; 30:jbcpp-2018-0150. [PMID: 31136300 DOI: 10.1515/jbcpp-2018-0150] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 02/15/2019] [Indexed: 01/16/2023]
Abstract
Background Antioxidant agents have positive effects on wound healing process and on the other hand probiotics also have great antioxidation or oxidation-resistance properties. Methods In this study, we investigated the effects of Lactobacillus reuteri derived ointment as a probiotic bacterium on the wound healing process using a full-thickness rat skin model. The wound diameter and contraction percent measurement, histopathological examination, and myeloperoxidase (MPO) enzyme activity evaluation were carried out during the period of study. Results Amount of deposit collagen was significantly increased; epithelization speed and epidermis production were also observed in the ointment-treated group, while the inflammation rate was also significantly lower than the control group. In addition, a significant reduction in the activity of enzyme MPO was also detected in the ointment-treated group. Conclusions According to the results, probiotic ointment effectively accelerates the wound healing process and it can be used as a promising drug for wound dressing application.
Collapse
Affiliation(s)
- Zohreh Khodaii
- Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Eshteraki Blvd. Baghestan, Karaj 9779453, Iran, Phone: +98 2634336007, Fax:+98 2634319188.,Department of Biochemistry, Genetics and Nutrition, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| | - Saman Afrasiabi
- Student Research Committee, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| | - Seied Ali Hashemi
- Department of Pathology, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| | | | - Mahboobeh Mehrabani Natanzi
- Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Eshteraki Blvd. Baghestan, Karaj 9779453, Iran, Phone: +98 2634336007, Fax:+98 2634319188.,Department of Biochemistry, Genetics and Nutrition, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| |
Collapse
|
168
|
A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements. BIOMED RESEARCH INTERNATIONAL 2019; 2019:3291367. [PMID: 31211135 PMCID: PMC6532319 DOI: 10.1155/2019/3291367] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 04/16/2019] [Indexed: 12/13/2022]
Abstract
Probiotics are now recognized for several health benefits and they have been recommended as a complementary therapeutic agent for metabolic disorders. Obesity is an altered health condition, which is a resultant of irregular energy intake and energy balance, changes in gut microbiota, and improper diet with the influence of genetic makeup and environmental factors. Several studies revealed the influence of probiotic supplementation on obesity-associated consequences in vitro, in vivo, and in human clinical studies. The current manuscript discussed the factors influencing the occurrence of obesity, the interplay between microbiome and obesity, the effect of the probiotic intervention on the health status of obese people, and possible mechanism of antiobesity activity of probiotics. The literature survey revealed that the antiobese activity of probiotics might be associated with their ability to alter the intestinal microbiota, remodeling of energy metabolism, alter the expression of genes related to thermogenesis, glucose metabolism, and lipid metabolism, and change the parasympathetic nerve activity. Further intense research is necessary to figure out the best probiotic or synbiotic mixture and optimum dosage and duration of the intervention to reduce obesity and prevent the recurring of obese condition.
Collapse
|
169
|
Ji Y, Park S, Chung Y, Kim B, Park H, Huang E, Jeong D, Jung HY, Kim B, Hyun CK, Holzapfel WH. Amelioration of obesity-related biomarkers by Lactobacillus sakei CJLS03 in a high-fat diet-induced obese murine model. Sci Rep 2019; 9:6821. [PMID: 31048785 PMCID: PMC6497927 DOI: 10.1038/s41598-019-43092-y] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 04/10/2019] [Indexed: 12/17/2022] Open
Abstract
Recent progresses in clinical diagnostic analyses have demonstrated the decisive influence of host gut microbiota on the status of metabolic disorders. Short chain fatty acids (SCFAs) produced by gut microbiota, in particular, are considered as a key biomarker, both of communication between gut microbiota and the host, and of impact on host metabolic homeostasis. Microbiota modulation and concomitant anti-obesity effects of probiotics have been reported by different researchers. However, the underlying modulatory functions of probiotics on gut microbiota towards host metabolic homeostasis are still not fully understood. In this study, the impact of Lactobacillus sakei CJLS03 (isolated from Korean kimchi) on obesity-related biomarkers was investigated using a diet-induced obese mouse model. Body weight increase, SCFAs, the gut microbiota and various obesity-associated biomarkers were significantly and beneficially influenced by L. sakei CJLS03 administration compared to the control groups. Analytical data on faecal samples support the role of the colonic microbial population in SCFA production. The composition of the latter may be influenced by modulation of the distal gastro-intestinal microbiota by putative probiotics such as L. sakei CJLS03.
Collapse
Affiliation(s)
- Yosep Ji
- Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
| | - Soyoung Park
- Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
| | - Youngmee Chung
- CJ Blossom Park, 42, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16495, Republic of Korea
| | - Bobae Kim
- Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
- School of Life Science, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
| | - Haryung Park
- Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
| | - Eunchong Huang
- Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
| | - Dahye Jeong
- CJ Blossom Park, 42, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16495, Republic of Korea
| | - Hoe-Yune Jung
- Department of Life Science, Division of Integrative Biosciences and Biotechnology, POSTECH, Pohang, Gyungbuk, 37673, Republic of Korea
| | - Bongjoon Kim
- CJ Blossom Park, 42, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16495, Republic of Korea
| | - Chang-Kee Hyun
- Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
- School of Life Science, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea
| | - Wilhelm H Holzapfel
- Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, 37554, Republic of Korea.
| |
Collapse
|
170
|
Lutkemeyer DDS, Do Amaral MA, Ishida Assunção NH, Marques Tejada NF, Saraiva Camara NO. Obesidade: uma abordagem inflamatória e microbiana. HU REVISTA 2019. [DOI: 10.34019/1982-8047.2018.v44.13963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A obesidade está intimamente ligada ao estado inflamatório, sendo considerada uma patologia metabólica complexa. Dietas hipercalóricas alteram a composição da microbiota intestinal, sendo a mudança da proporção de bactérias dos filos Bacteroidetes e Firmicutes uma das consequências mais conhecidas. Essa mudança determina a produção de metabólitos específicos do sistema imune, induzindo estado inflamatório responsável pelo agravamento de uma série de doenças. A dieta hipercalórica representa um fator de risco para a obesidade e para o diabetes mellitus, doenças interligadas pelo conceito de lipotoxicidade, e o estado inflamatório também contribui para o aparecimento e para a progressão de doenças cardiovasculares. Com esse artigo, objetivamos estudar a obesidade pela perspectiva imunológica e microbiológica, abordando as consequências de dietas hipercalóricas sobre o estado inflamatório e a sobre a microbiota. Ademais, associar a mudança no microbioma a doenças prevalentes como o diabetes mellitus e as doenças cardiovasculares, apontando abordagens terapêuticas potenciais.
Collapse
|
171
|
Weight loss probiotic supplementation effect in overweight and obesity subjects: A review. Clin Nutr 2019; 39:694-704. [PMID: 30987812 DOI: 10.1016/j.clnu.2019.03.034] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 03/08/2019] [Accepted: 03/26/2019] [Indexed: 12/19/2022]
Abstract
Obese individuals present adverse changes in the diversity and composition of the gut microbiota, leading to alterations in energy balance, lipid metabolism, endocrine disturbances, and low-grade chronic systemic inflammation increases. Probiotic supplementation appears to change gut microbiota by decrease gut permeability, inflammation, and metabolic disorders, creating a promising environment to weight loss. This revision resumes the main findings of probiotic supplementation and weight loss that contributed to building the current background linking changes in gut microbiota profile and with obesity.
Collapse
|
172
|
Effects of cereal beta-glucan consumption on body weight, body mass index, waist circumference and total energy intake: A meta-analysis of randomized controlled trials. Complement Ther Med 2019; 43:131-139. [DOI: 10.1016/j.ctim.2019.01.018] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Revised: 01/14/2019] [Accepted: 01/18/2019] [Indexed: 12/15/2022] Open
|
173
|
Koutnikova H, Genser B, Monteiro-Sepulveda M, Faurie JM, Rizkalla S, Schrezenmeir J, Clément K. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2019; 9:e017995. [PMID: 30928918 PMCID: PMC6475231 DOI: 10.1136/bmjopen-2017-017995] [Citation(s) in RCA: 152] [Impact Index Per Article: 30.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVE To systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease. DESIGN Systematic review and meta-analysis. DATA SOURCES Medline, EMBASE and COCHRANE from 1990 to June 2018. ELIGIBILITY CRITERIA Randomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children <3 years. RESULTS One hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=-0.94 kg mean difference, 95% CI -1.17 to -0.70, I²=0.0%), body mass index (k=32, d=-0.55 kg/m², 95% CI -0.86 to -0.23, I²=91.9%), waist circumference (k=13, d=-1.31 cm, 95% CI -1.79 to -0.83, I²=14.5%), body fat mass (k=11, d=-0.96 kg, 95% CI -1.21 to -0.71, I²=0.0%) and visceral adipose tissue mass (k=5, d=-6.30 cm², 95% CI -9.05 to -3.56, I²=0.0%). In type 2 diabetics, probiotics reduced fasting glucose (k=19, d=-0.66 mmol/L, 95% CI -1.00 to -0.31, I²=27.7%), glycated haemoglobin (k=13, d=-0.28 pp, 95% CI -0.46 to -0.11, I²=54.1%), insulin (k=13, d=-1.66 mU/L, 95% CI -2.70 to -0.61, I²=37.8%) and homeostatic model of insulin resistance (k=10, d=-1.05 pp, 95% CI -1.48 to -0.61, I²=18.2%). In subjects with fatty liver diseases, probiotics reduced alanine (k=12, d=-10.2 U/L, 95% CI -14.3 to -6.0, I²=93.50%) and aspartate aminotransferases (k=10, d=-9.9 U/L, 95% CI -14.1 to -5.8, I²=96.1%). These improvements were mostly observed with bifidobacteria (Bifidobacterium breve, B. longum), Streptococcus salivarius subsp. thermophilus and lactobacilli (Lactobacillus acidophilus, L. casei, L. delbrueckii) containing mixtures and influenced by trials conducted in one country. CONCLUSIONS The intake of probiotics resulted in minor but consistent improvements in several metabolic risk factors in subjects with metabolic diseases. TRIAL REGISTRATION NUMBER CRD42016033273.
Collapse
Affiliation(s)
| | - Bernd Genser
- BGStats Consulting, Vienna, Austria
- Mannheimer Institut fur Public Health, Ruprecht Karls Universitat Heidelberg, Mannheim, Baden-Württemberg, Germany
| | - Milena Monteiro-Sepulveda
- Nutrition Department, Pitie-Salpêtrière hospital, Institute of Cardiometabolism and Nutrition, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Salwa Rizkalla
- Nutrition Department, Pitie-Salpêtrière hospital, Institute of Cardiometabolism and Nutrition, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jürgen Schrezenmeir
- Clinical Research Center Kiel, Johannes Gutenberg Universitat Universitatsmedizin, Mainz, Rheinland-Pfalz, Germany
| | - Karine Clément
- Nutrition Department, Pitie-Salpêtrière hospital, Institute of Cardiometabolism and Nutrition, Assistance Publique-Hôpitaux de Paris, Paris, France
- Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), NutriOmiCs team, UMR S 1269, Paris, France
| |
Collapse
|
174
|
Suzumura EA, Bersch-Ferreira ÂC, Torreglosa CR, da Silva JT, Coqueiro AY, Kuntz MGF, Chrispim PP, Weber B, Cavalcanti AB. Effects of oral supplementation with probiotics or synbiotics in overweight and obese adults: a systematic review and meta-analyses of randomized trials. Nutr Rev 2019; 77:430-450. [DOI: 10.1093/nutrit/nuz001] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Affiliation(s)
- Erica A Suzumura
- Research Institute at Hospital do Coração, São Paulo, Brazil
- Department of Preventive Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
| | | | | | | | - Audrey Y Coqueiro
- Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | | | | | | | | |
Collapse
|
175
|
Ji Y, Chung YM, Park S, Jeong D, Kim B, Holzapfel WH. Dose-dependent and strain-dependent anti-obesity effects of Lactobacillus sakei in a diet induced obese murine model. PeerJ 2019; 7:e6651. [PMID: 30923658 PMCID: PMC6431538 DOI: 10.7717/peerj.6651] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Accepted: 02/20/2019] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Overweight and abdominal obesity, in addition to medical conditions such as high blood pressure, high blood sugar and triglyceride levels, are typical risk factors associated with metabolic syndrome. Yet, considering the complexity of factors and underlying mechanisms leading to these inflammatory conditions, a deeper understanding of this area is still lacking. Some probiotics have a reputation of a relatively-long history of safe use, and an increasing number of studies are confirming benefits including anti-obesity effects when administered in adequate amounts. Recent reports demonstrate that probiotic functions may widely differ with reference to either intra-species or inter-species related data. Such differences do not necessarily reflect or explain strain-specific functions of a probiotic, and thus require further assessment at the intra-species level. Various anti-obesity clinical trials with probiotics have shown discrepant results and require additional consolidated studies in order to clarify the correct dose of application for reliable and constant efficacy over a long period. METHODS Three different strains of Lactobacillus sakei were administered in a high-fat diet induced obese murine model using three different doses, 1 × 1010, 1 × 109 and 1 × 108 CFUs, respectively, per day. Changes in body and organ weight were monitored, and serum chemistry analysis was performed for monitoring obesity associated biomarkers. RESULTS Only one strain of L. sakei (CJLS03) induced a dose-dependent anti-obesity effect, while no correlation with either dose or body or adipose tissue weight loss could be detected for the other two L. sakei strains (L338 and L446). The body weight reduction primarily correlated with adipose tissue and obesity-associated serum biomarkers such as triglycerides and aspartate transaminase. DISCUSSION This study shows intraspecies diversity of L. sakei and suggests that anti-obesity effects of probiotics may vary in a strain- and dose-specific manner.
Collapse
Affiliation(s)
- Yosep Ji
- Department of Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, South Korea
| | - Young Mee Chung
- Beneficial Microbes Center, CJ Foods R&D, CJ CheilJedang Corporation, Suwon, Gyeonggi, South Korea
| | - Soyoung Park
- Department of Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, South Korea
| | - Dahye Jeong
- Beneficial Microbes Center, CJ Foods R&D, CJ CheilJedang Corporation, Suwon, Gyeonggi, South Korea
| | - Bongjoon Kim
- Beneficial Microbes Center, CJ Foods R&D, CJ CheilJedang Corporation, Suwon, Gyeonggi, South Korea
| | - Wilhelm Heinrich Holzapfel
- Department of Advanced Green Energy and Environment, Handong Global University, Pohang, Gyungbuk, South Korea
| |
Collapse
|
176
|
Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep 2019; 9:4812. [PMID: 30886158 PMCID: PMC6423325 DOI: 10.1038/s41598-019-39602-7] [Citation(s) in RCA: 86] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 12/19/2018] [Indexed: 12/11/2022] Open
Abstract
Lactobacillus gasseri SBT2055 (LG2055) is a probiotic lactic acid bacterium with multifunctional effects, including the prevention of influenza A virus infection in mice, reduction of adipocyte size in mice, and increased lifespan in C. elegans. We investigated whether LG2055 exhibits antiviral activity against respiratory syncytial virus (RSV), a global pathogen for which a preventive strategy is required. Following oral administration of LG2055 in mice, the RSV titre in the lung was significantly decreased, while body weight was not decreased after virus infection. Additionally, the elevated expression of pro-inflammatory cytokines in the lung upon RSV infection decreased after LG2055 administration. Moreover, interferon and interferon stimulated genes were upregulated by LG2055 treatment. Comparative cellular proteomic analysis revealed that SWI2/SNF2-related CREB-binding protein activator protein (SRCAP) was a candidate for the antiviral activity of LG2055 against RSV. There was a positive correlation between the inhibition of RSV replication and the suppression of SRCAP expression and RSV replication was suppressed by SRCAP silencing. Since SRCAP is a scaffold protein to which viral non-structural proteins bind, the downregulation of SRCAP induced by LG2055 could provide new insights about the inhibition of RSV replication. In summary, our study demonstrated that LG2055 has prophylactic potential against RSV infection.
Collapse
|
177
|
Cerdó T, García-Santos JA, G Bermúdez M, Campoy C. The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. Nutrients 2019; 11:E635. [PMID: 30875987 PMCID: PMC6470608 DOI: 10.3390/nu11030635] [Citation(s) in RCA: 195] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2019] [Revised: 03/06/2019] [Accepted: 03/11/2019] [Indexed: 02/06/2023] Open
Abstract
Obesity is a global pandemic complex to treat due to its multifactorial pathogenesis-an unhealthy lifestyle, neuronal and hormonal mechanisms, and genetic and epigenetic factors are involved. Scientific evidence supports the idea that obesity and metabolic consequences are strongly related to changes in both the function and composition of gut microbiota, which exert an essential role in modulating energy metabolism. Modifications of gut microbiota composition have been associated with variations in body weight and body mass index. Lifestyle modifications remain as primary therapy for obesity and related metabolic disorders. New therapeutic strategies to treat/prevent obesity have been proposed, based on pre- and/or probiotic modulation of gut microbiota to mimic that found in healthy non-obese subjects. Based on human and animal studies, this review aimed to discuss mechanisms through which gut microbiota could act as a key modifier of obesity and related metabolic complications. Evidence from animal studies and human clinical trials suggesting potential beneficial effects of prebiotic and various probiotic strains on those physical, biochemical, and metabolic parameters related to obesity is presented. As a conclusion, a deeper knowledge about pre-/probiotic mechanisms of action, in combination with adequately powered, randomized controlled follow-up studies, will facilitate the clinical application and development of personalized healthcare strategies.
Collapse
Affiliation(s)
- Tomás Cerdó
- Department of Pediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.
- EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre, University of Granada, 18016 Granada, Spain.
- Instituto de Investigación Biosanitaria ibs, GRANADA, Health Sciences Technological Park, 18012 Granada, Spain.
| | - José Antonio García-Santos
- Department of Pediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.
- EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre, University of Granada, 18016 Granada, Spain.
- Instituto de Investigación Biosanitaria ibs, GRANADA, Health Sciences Technological Park, 18012 Granada, Spain.
| | - Mercedes G Bermúdez
- Department of Pediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.
- EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre, University of Granada, 18016 Granada, Spain.
- Instituto de Investigación Biosanitaria ibs, GRANADA, Health Sciences Technological Park, 18012 Granada, Spain.
| | - Cristina Campoy
- Department of Pediatrics, School of Medicine, University of Granada, Avda. Investigación 11, 18016 Granada, Spain.
- EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre, University of Granada, 18016 Granada, Spain.
- Instituto de Investigación Biosanitaria ibs, GRANADA, Health Sciences Technological Park, 18012 Granada, Spain.
- Spanish Network of Biomedical Research in Epidemiology and Public Health (CIBERESP), Granada's node, Carlos III Health Institute of Health Carlos III, 28029 Madrid, Spain.
| |
Collapse
|
178
|
Milk fermented with Lactobacillus casei NCDC19 improves high fat and sucrose diet alters gene expression in obese mice. Int Dairy J 2019. [DOI: 10.1016/j.idairyj.2018.11.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
179
|
Metabolic improvement in obese patients after duodenal-jejunal exclusion is associated with intestinal microbiota composition changes. Int J Obes (Lond) 2019; 43:2509-2517. [PMID: 30765893 DOI: 10.1038/s41366-019-0336-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 12/21/2018] [Accepted: 01/16/2019] [Indexed: 12/23/2022]
Abstract
BACKGROUND Intestinal microbiota have been suggested to play an important role in the pathogenesis of obesity and type 2 diabetes. Bariatric surgery improves both conditions and has been associated with changes in intestinal microbiota composition. We investigated the effect of a nonsurgical bariatric technique on intestinal microbiota composition in relation to metabolic improvement. METHODS Seventeen patients with obesity and type 2 diabetes were treated with the nonsurgical duodenal-jejunal bypass liner, which excludes the proximal 60 cm small intestine from food. Fecal samples as well as metabolic parameters reflecting obesity and type 2 diabetes were obtained from the patients at baseline, after 6 months with the device in situ, and 6 months after explantation. RESULTS After 6 months of treatment, both obesity and type 2 diabetes had improved with a decrease in weight from 106.1 [99.4-123.5] to 97.4 [89.4-114.0] kg and a decrease in HbA1c from 8.5% [7.6-9.2] to 7.2% [6.3-8.1] (both p < 0.05). This was paralleled by an increased abundance of typical small intestinal bacteria such as Proteobacteria, Veillonella, and Lactobacillus spp. in feces. After removal of the duodenal-jejunal bypass liner, fecal microbiota composition was similar to that observed at baseline, despite persistent weight loss. CONCLUSION Improvement of obesity and type 2 diabetes after exclusion of the proximal 60 cm small intestine by treatment with a nonsurgical duodenal-jejunal bypass liner may be promoted by changes in fecal microbiota composition.
Collapse
|
180
|
Zolotukhin PV, Prazdnova EV, Chistyakov VA. Methods to Assess the Antioxidative Properties of Probiotics. Probiotics Antimicrob Proteins 2019; 10:589-599. [PMID: 29249065 DOI: 10.1007/s12602-017-9375-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Probiotics prove useful in correcting and preventing numerous health conditions, including those having severe impact on society, e.g., obesity and cancer. Notably, these capabilities of probiotics appear to be associated with their antioxidant properties. The mechanisms of antioxidant action of probiotics range from immediate biochemical scavenging of reactive substances to induction of signaling events leading to increased capacity of the host's cytoprotective systems. Since the antioxidant effects of probiotics significantly vary in types and details, a broad selection of methods of assessment of these properties is required in order to identify, characterize, and develop novel probiotics for medical purposes, as well as to explain the mechanisms of action of probiotics already in use in healthcare. This review revises the versatile toolbox, which can be used to assess the antioxidant properties of probiotics.
Collapse
|
181
|
Ke X, Walker A, Haange SB, Lagkouvardos I, Liu Y, Schmitt-Kopplin P, von Bergen M, Jehmlich N, He X, Clavel T, Cheung PCK. Synbiotic-driven improvement of metabolic disturbances is associated with changes in the gut microbiome in diet-induced obese mice. Mol Metab 2019; 22:96-109. [PMID: 30792016 PMCID: PMC6437638 DOI: 10.1016/j.molmet.2019.01.012] [Citation(s) in RCA: 91] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Revised: 01/29/2019] [Accepted: 01/30/2019] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVE The gut microbiota is an important influencing factor of metabolic health. Although dietary interventions with probiotics, prebiotics, and synbiotics can be effective means to regulate obesity and associated comorbidities, the underlying shifts in gut microbial communities, especially at the functional level, have not been characterized in great details. In this study, we sought to investigate the effects of synbiotics on the regulation of gut microbiota and the alleviation of high-fat diet (HFD)-induced metabolic disorders in mice. METHODS Specific pathogen-free (SPF) male C57BL/6J mice were fed diets with either 10% (normal diet, ND) or 60% (high-fat diet, HFD) of total calories from fat (lard). Dietary interventions in the HFD-fed mice included (i) probiotic (Bifidobacterium animalis subsp. lactis and Lactobacillus paracasei subsp. paracasei DSM 46331), (ii) prebiotic (oat β-glucan), and (iii) synbiotic (a mixture of i and ii) treatments for 12 weeks. Besides detailed characterization of host metabolic parameters, a multi-omics approach was used to systematically profile the microbial signatures at both the phylogenetic and functional levels using 16S rRNA gene sequencing, metaproteomics and targeted metabolomics analysis. RESULTS The synbiotic intervention significantly reduced body weight gain and alleviated features of metabolic complications. At the phylogenetic level, the synbiotic treatment significantly reversed HFD-induced changes in microbial populations, both in terms of richness and the relative abundance of specific taxa. Potentially important species such as Faecalibaculum rodentium and Alistipes putredinis that might mediate the beneficial effects of the synbiotic were identified. At the functional level, short-chain fatty acid and bile acid profiles revealed that all dietary interventions significantly restored cecal levels of acetate, propionate, and butyrate, while the synbiotic treatment reduced the bile acid pools most efficiently. Metaproteomics revealed that the effects of the synbiotic intervention might be mediated through metabolic pathways involved in carbohydrate, amino acid, and energy metabolisms. CONCLUSIONS Our results suggested that dietary intervention using the novel synbiotic can alleviate HFD-induced weight gain and restore gut microbial ecosystem homeostasis phylogenetically and functionally.
Collapse
Affiliation(s)
- Xinxin Ke
- School of Life Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
| | - Alesia Walker
- Research Unit Analytical BioGeoChemistry, HelmholtzZentrum München, Neuherberg, Germany
| | - Sven-Bastiaan Haange
- Helmholtz-Centre for Environmental Research-UFZ, Department of Molecular Systems Biology, Leipzig, Germany
| | - Ilias Lagkouvardos
- ZIEL Institute for Food and Health, Technical University of Munich, Freising, Germany
| | - Yuwen Liu
- Department of Human Genetics, The University of Chicago, Chicago, IL, 60615, USA; Department of Pig Genomic Design and Breeding, Agricultural Genome Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen 518124, China
| | - Philippe Schmitt-Kopplin
- Research Unit Analytical BioGeoChemistry, HelmholtzZentrum München, Neuherberg, Germany; ZIEL Institute for Food and Health, Technical University of Munich, Freising, Germany; Chair of Analytical Food Chemistry, Technische Universität München, Freising-Weihenstephan, Germany
| | - Martin von Bergen
- Helmholtz-Centre for Environmental Research-UFZ, Department of Molecular Systems Biology, Leipzig, Germany
| | - Nico Jehmlich
- Helmholtz-Centre for Environmental Research-UFZ, Department of Molecular Systems Biology, Leipzig, Germany
| | - Xin He
- Department of Human Genetics, The University of Chicago, Chicago, IL, 60615, USA
| | - Thomas Clavel
- ZIEL Institute for Food and Health, Technical University of Munich, Freising, Germany; University Hospital of RWTH Aachen, Functional Microbiome Research Group, Institute of Medical Microbiology, Aachen, Germany
| | - Peter C K Cheung
- School of Life Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.
| |
Collapse
|
182
|
Milard M, Laugerette F, Durand A, Buisson C, Meugnier E, Loizon E, Louche-Pelissier C, Sauvinet V, Garnier L, Viel S, Bertrand K, Joffre F, Cheillan D, Humbert L, Rainteau D, Plaisancié P, Bindels LB, Neyrinck AM, Delzenne NM, Michalski MC. Milk Polar Lipids in a High-Fat Diet Can Prevent Body Weight Gain: Modulated Abundance of Gut Bacteria in Relation with Fecal Loss of Specific Fatty Acids. Mol Nutr Food Res 2019; 63:e1801078. [DOI: 10.1002/mnfr.201801078] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Revised: 12/18/2018] [Indexed: 01/14/2023]
Affiliation(s)
- Marine Milard
- Univ Lyon; CarMeN Laboratory; INSERM U1060; INRA U1397; INSA Lyon; Université Claude Bernard Lyon 1; 69621 Villeurbanne France
| | - Fabienne Laugerette
- Univ Lyon; CarMeN Laboratory; INSERM U1060; INRA U1397; INSA Lyon; Université Claude Bernard Lyon 1; 69621 Villeurbanne France
| | - Annie Durand
- Univ Lyon; CarMeN Laboratory; INSERM U1060; INRA U1397; INSA Lyon; Université Claude Bernard Lyon 1; 69621 Villeurbanne France
| | - Charline Buisson
- Univ Lyon; CarMeN Laboratory; INSERM U1060; INRA U1397; INSA Lyon; Université Claude Bernard Lyon 1; 69621 Villeurbanne France
| | - Emmanuelle Meugnier
- Univ Lyon; CarMeN Laboratory; INSERM; INRA; INSA Lyon; Université Claude Bernard Lyon 1; 69600 Oullins France
| | - Emmanuelle Loizon
- Univ Lyon; CarMeN Laboratory; INSERM; INRA; INSA Lyon; Université Claude Bernard Lyon 1; 69600 Oullins France
| | - Corinne Louche-Pelissier
- Centre de Recherche en Nutrition Humaine (CRNH) Rhône-Alpes; Centre Européen Pour la Nutrition et la Santé; Centre Hospitalier Lyon Sud; Université Claude Bernard Lyon 1; INSERM, Hospices Civils de Lyon F-69310 Pierre Bénite France
| | - Valérie Sauvinet
- Centre de Recherche en Nutrition Humaine (CRNH) Rhône-Alpes; Centre Européen Pour la Nutrition et la Santé; Centre Hospitalier Lyon Sud; Université Claude Bernard Lyon 1; INSERM, Hospices Civils de Lyon F-69310 Pierre Bénite France
| | - Lorna Garnier
- Laboratoire d'Immunologie; Hospices Civils de Lyon; Centre Hospitalier Lyon Sud; Pierre-Bénite France
| | - Sébastien Viel
- Laboratoire d'Immunologie; Hospices Civils de Lyon; Centre Hospitalier Lyon Sud; Pierre-Bénite France
| | | | | | - David Cheillan
- Univ Lyon; CarMeN Laboratory; INSERM U1060; INRA U1397; INSA Lyon; Université Claude Bernard Lyon 1; 69621 Villeurbanne France
- Service Biochimie et Biologie Moléculaire Grand Est; Centre de Biologie Est; Hospices Civils de Lyon; Lyon France
| | - Lydie Humbert
- Sorbonne Universités; UPMC Univ. Paris 06; École normale supérieure; PSL Research University; CNRS, INSERM, APHP, Laboratoire des Biomolécules (LBM), 27 rue de Chaligny Paris 75005 France
| | - Dominique Rainteau
- Sorbonne Universités; UPMC Univ. Paris 06; École normale supérieure; PSL Research University; CNRS, INSERM, APHP, Laboratoire des Biomolécules (LBM), 27 rue de Chaligny Paris 75005 France
| | - Pascale Plaisancié
- Univ Lyon; CarMeN Laboratory; INSERM U1060; INRA U1397; INSA Lyon; Université Claude Bernard Lyon 1; 69621 Villeurbanne France
| | - Laure B. Bindels
- Louvain Drug Research Institute; Metabolism and Nutrition Research Group; Université catholique de Louvain; Brussels Belgium
| | - Audrey M. Neyrinck
- Louvain Drug Research Institute; Metabolism and Nutrition Research Group; Université catholique de Louvain; Brussels Belgium
| | - Nathalie M. Delzenne
- Louvain Drug Research Institute; Metabolism and Nutrition Research Group; Université catholique de Louvain; Brussels Belgium
| | - Marie-Caroline Michalski
- Univ Lyon; CarMeN Laboratory; INSERM U1060; INRA U1397; INSA Lyon; Université Claude Bernard Lyon 1; 69621 Villeurbanne France
| |
Collapse
|
183
|
Probiotics: How Effective Are They in the Fight against Obesity? Nutrients 2019; 11:nu11020258. [PMID: 30678355 PMCID: PMC6412733 DOI: 10.3390/nu11020258] [Citation(s) in RCA: 105] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Revised: 01/15/2019] [Accepted: 01/18/2019] [Indexed: 02/08/2023] Open
Abstract
Obesity has been associated with structural and functional changes in the gut microbiota. The abundance in, and diversity of, certain bacteria may favor energy harvest and metabolic pathways leading to obesity. Therefore, gut microbiota has become a potential target that can be manipulated to obtain optimal health. Probiotics have been shown to influence the composition of the gut microbiota, improve gut integrity, and restore the microbial shifts characteristic of obesity. Based on physical and biochemical parameters, metabolic and inflammatory markers, and alterations in gut microbe diversity, animal studies revealed beneficial results in obese models whereas the results in humans are sparse and inconsistent. Thus, the purpose of this review is to present evidence from animal studies and human clinical trials demonstrating the effects of various probiotic strains and their potential efficacy in improving obesity and associated metabolic dysfunctions. Furthermore, the review discusses current gaps in our understanding of how probiotics modulate gut microflora to protect against obesity. Finally, we propose future studies and methodological approaches that may shed light on the challenges facing the scientific community in deciphering the host–bacteria interaction in obesity.
Collapse
|
184
|
Ribeiro FM, Ribeiro CFA, G ACM, Castro AP, Almeida JA, Franco OL, Petriz BA. Limited Effects of Low-to-Moderate Aerobic Exercise on the Gut Microbiota of Mice Subjected to a High-Fat Diet. Nutrients 2019; 11:E149. [PMID: 30641996 PMCID: PMC6357116 DOI: 10.3390/nu11010149] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Revised: 12/26/2018] [Accepted: 01/03/2019] [Indexed: 12/20/2022] Open
Abstract
Several studies have indicated that diet and exercise may modulate the gut microbiota in obese subjects. Both interventions were shown to alter the microbiota orthogonally. However, this relationship has not been fully explored. This study analyzed the effects of low-to-moderate aerobic training on the fecal microbiota of mice subjected to a high-fat diet (HFD). Here, 40 male mice (C57Bl/6) were divided into two groups with standard diet (SD; 12.4% lipid) and HFD (60.3% lipid) for four months. These groups were divided into four, named SD control, HF control, SD trained and HF trained. All animals were submitted to an incremental test to estimate low-to-moderate maximum speed. Training consisted of 30 min·day-1, 5 days/week, for 8 weeks. The HFD increased the body weight (p < 0.0001) and adiposity index (p < 0.05). HFD also negatively influenced performance in exercise training. Moreover, the diversity of gut microbiota was reduced by the HFD in all groups. A low-to-moderate exercise was ineffective in modulating the gut microbiota composition in mice subjected to HFD. These findings suggest that two months of low-to-moderate exercise does not achieve a preponderant modulatory effect on shaping microbiota when submitted to the high-fat diet.
Collapse
Affiliation(s)
- Filipe M Ribeiro
- Post-Graduation Program in Physical Education, Catholic University of Brasilia, Brasilia, 71966-700, DF, Brazil.
- Center for Proteomic and Biochemical Analysis, Post-Graduation in Genomic and Biotechnology Sciences, Catholic University of Brasilia, Brasília, 71966-700, DF, Brazil.
- University Center-UDF, Research Group of Molecular Exercise Physiology, Brasilia, 70390-045 DF, Brazil.
| | - Camila F A Ribeiro
- S-Inova Biotech, Catholic University Dom Bosco, Biotechnology Program, Campo Grande, 79000-000, MS, Brazil.
| | - Ana Cláudia M G
- University Center-UDF, Research Group of Molecular Exercise Physiology, Brasilia, 70390-045 DF, Brazil.
| | - Alinne P Castro
- S-Inova Biotech, Catholic University Dom Bosco, Biotechnology Program, Campo Grande, 79000-000, MS, Brazil.
| | - Jeeser A Almeida
- Programa de Pós-Graduação em Saúde e Desenvolvimento na Região Centro Oeste-PPGSD, Faculdade de Medicina-FAMED, Universidade Federal de Mato Grosso do Sul, Campo Grande, 71966-700, MS, Brazil.
| | - Octavio L Franco
- Center for Proteomic and Biochemical Analysis, Post-Graduation in Genomic and Biotechnology Sciences, Catholic University of Brasilia, Brasília, 71966-700, DF, Brazil.
- S-Inova Biotech, Catholic University Dom Bosco, Biotechnology Program, Campo Grande, 79000-000, MS, Brazil.
| | - Bernardo A Petriz
- Center for Proteomic and Biochemical Analysis, Post-Graduation in Genomic and Biotechnology Sciences, Catholic University of Brasilia, Brasília, 71966-700, DF, Brazil.
- University Center-UDF, Research Group of Molecular Exercise Physiology, Brasilia, 70390-045 DF, Brazil.
| |
Collapse
|
185
|
Li Y, Liu T, Zhao M, Zhong H, Luo W, Feng F. In vitro and in vivo investigations of probiotic properties of lactic acid bacteria isolated from Chinese traditional sourdough. Appl Microbiol Biotechnol 2019; 103:1893-1903. [DOI: 10.1007/s00253-018-9554-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 11/20/2018] [Accepted: 12/06/2018] [Indexed: 12/17/2022]
|
186
|
Ejtahed HS, Angoorani P, Soroush AR, Atlasi R, Hasani-Ranjbar S, Mortazavian AM, Larijani B. Probiotics supplementation for the obesity management; A systematic review of animal studies and clinical trials. J Funct Foods 2019. [DOI: 10.1016/j.jff.2018.10.039] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
187
|
Grover S, Patil A, Kaur A, Garg G. Probiotics: A Potential Immunotherapeutic Approach for the Treatment of Schizophrenia. J Pharm Bioallied Sci 2019; 11:321-327. [PMID: 31619913 PMCID: PMC6791081 DOI: 10.4103/jpbs.jpbs_47_19] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Probiotics are in use for physiological boosting, health supplement, and for treatment since historical time. Recently, the to-and-fro pathways linking the gut with the brain, explaining the indirect communication via modulation of immune function and levels of various neurotransmitters, have been discovered, but how precisely these modulations alter the levels of neurotransmitters contributing to the cognitive and other symptom improvements in patients with schizophrenia remains a new arena of research for psychiatry and psychology professionals. The germ-free mice experiments have been the game changer in the mechanistic exploration. The antimicrobial usage alters the local gut flora and hence is associated with psychiatric side effects that strengthen the association further. The changes in the genetics of these bacteria with different types of diet and its correlation with neurotransmitters production capacity and the psyche of the individual are indeed an emerging field for schizophrenia research. Redressal of issues such as manufacturing, the shelf life of probiotics, and stability of probiotics in the gut milieu, in the presence of food, secretions, and exact volume needed for particular age group will help in refining the dose duration of probiotic therapy. Clinical trials are underway for evaluating safety and efficacy in schizophrenia. The gut microorganism transplant and pharmacovigilance of probiotics are important areas yet to be addressed accurately. This paper elucidates the pathways, clinical studies, availability of probiotics in the Indian market with their composition, regulatory issues in India about the probiotic use, and future of probiotic research in schizophrenia.
Collapse
Affiliation(s)
- Sandeep Grover
- Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Amol Patil
- Department of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Anit Kaur
- Department of Paediatrics, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Gaurav Garg
- Department of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| |
Collapse
|
188
|
Takahashi K, Maeta A, Asano M, Iguchi T, Segawa T. Influence of Multi-grain koji Supplementation on Body Fat Reduction in Rats Consuming a High Fat Diet and in 20 Young Women: A Single-blind Placebo-controlled Intervention Study in a Single Center. FOOD SCIENCE AND TECHNOLOGY RESEARCH 2019. [DOI: 10.3136/fstr.25.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Kyoko Takahashi
- Department of Food Science and Nutrition, School of Human Environmental Sciences, Mukogawa Women's University
| | - Akihiro Maeta
- Department of Food Science and Nutrition, School of Human Environmental Sciences, Mukogawa Women's University
| | - Mariko Asano
- Department of Food Science and Nutrition, School of Human Environmental Sciences, Mukogawa Women's University
| | | | | |
Collapse
|
189
|
Venkatakrishnan K, Chiu HF, Wang CK. Extensive review of popular functional foods and nutraceuticals against obesity and its related complications with a special focus on randomized clinical trials. Food Funct 2019; 10:2313-2329. [DOI: 10.1039/c9fo00293f] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Weight management (anti-obesity) by popular functional foods and nutraceuticals.
Collapse
Affiliation(s)
- Kamesh Venkatakrishnan
- School of Nutrition
- Chung Shan Medical University
- Taichung City-40201
- Taiwan
- Republic of China
| | - Hui-Fang Chiu
- Department of Chinese Medicine
- Taichung Hospital Ministry of Health and Welfare
- Taichung-40301
- Taiwan
- Republic of China
| | - Chin-Kun Wang
- School of Nutrition
- Chung Shan Medical University
- Taichung City-40201
- Taiwan
- Republic of China
| |
Collapse
|
190
|
Khalili L, Alipour B, Asghari Jafarabadi M, Hassanalilou T, Mesgari Abbasi M, Faraji I. Probiotic assisted weight management as a main factor for glycemic control in patients with type 2 diabetes: a randomized controlled trial. Diabetol Metab Syndr 2019; 11:5. [PMID: 30675190 PMCID: PMC6334408 DOI: 10.1186/s13098-019-0400-7] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Accepted: 01/04/2019] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVES To evaluate the effect of Lactobacillus casei 01 on dietary intake, body weight, and glycemic control in patients with T2DM. METHOD Forty patients with T2DM (n = 20 for each group) were assigned into two groups in present trial. The patients in the probiotic group received a daily capsule containing a minimum of 108 CFU of L. casei 01 for 8 week. The placebo group took capsules filled with maltodextrin for the same time period. Dietary intake questionnaires and anthropometric measurements were collected, and the participants were assessed by an endocrinologist at baseline and at the end of the trial. RESULTS Lactobacillus casei 01 supplementation significantly decreased total energy, carbohydrate, fat, and protein intake compared with placebo (p = 0.001, p = 0.002, p = 0.009, p = 0.001; respectively). Moreover weight, BMI, and waist circumference were significantly decreased in intervention group compared with placebo group (p < 0.001; p < 0.001; p = 0.029; respectively). In comparison with placebo group serum fetuin-A level, fasting blood sugar, insulin concentration, and insulin resistance were significantly decreased (p = 0.023, p =0.013, p = 0.028; p = 0.007; respectively), and serum SIRT1 level was significantly increased (p = 0.040) in intervention group. CONCLUSIONS Lactobacillus casei 01 supplementation affected dietary intake and body weight in a way that improved fetuin-A and SIRT1 levels and glycemic response in subjects with T2DM. Affecting the fetuin-A and SIRT1 levels introduces a new known mechanism of probiotic action in diabetes management.
Collapse
Affiliation(s)
- Leila Khalili
- Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran
| | - Beitullah Alipour
- Department of Community Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran
| | - Mohammad Asghari Jafarabadi
- Department of Statistics and Epidemiology, Faculty of Health, Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran
| | - Tohid Hassanalilou
- Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran
| | - Mehran Mesgari Abbasi
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran
| | - Ismail Faraji
- Internist, Fellow of Endocrinology, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran
| |
Collapse
|
191
|
Chen HM, Chen CC, Chen CC, Wang SC, Wang CL, Huang CH, Liou JS, Liu TW, Peng HL, Lin FM, Liu CY, Weng SL, Cheng CJ, Hung YF, Liao CC, Huang HD. Gut microbiome changes in overweight male adults following bowel preparation. BMC Genomics 2018; 19:904. [PMID: 30598081 PMCID: PMC6311932 DOI: 10.1186/s12864-018-5285-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Background Human gut microbiome has an essential role in human health and disease. Although the major dominant microbiota within individuals have been reported, the change of gut microbiome caused by external factors, such as antibiotic use and bowel cleansing, remains unclear. We conducted this study to investigate the change of gut microbiome in overweight male adults after bowel preparation, where none of the participants had been diagnosed with any systemic diseases. Methods A total of 20 overweight, male Taiwanese adults were recruited, and all participants were omnivorous. The participants provided fecal samples and blood samples at three time points: prior to bowel preparation, 7 days after colonoscopy, and 28 days after colonoscopy. The microbiota composition in fecal samples was analyzed using 16S ribosome RNA gene amplicon sequencing. Results Our results demonstrated that the relative abundance of the most dominant bacteria hardly changed from prior to bowel preparation to 28 days after colonoscopy. Using the ratio of Prevotella to the sum of Prevotella and Bacteroides in the fecal samples at baseline, the participants were separated into two groups. The fecal samples of the Type 1 group was Bacteroides-dominant, and that of the Type 2 group was Prevotella-dominant with a noticeable presence Bacteroides. Bulleidia appears more in the Type 1 fecal samples, while Akkermensia appears more in the Type 2 fecal samples. Of each type, the gut microbial diversity differed slightly among the three collection times. Additionally, the Type 2 fecal microbiota was temporarily susceptible to bowel cleansing. Predictive functional analysis of microbial community reveals that their activities for the mineral absorption metabolism and arachidonic acid metabolism differed significantly between the two types. Depending on their fecal type, the variance of triglycerides and C-reactive protein also differed between the two types of participants. Conclusions Depending upon the fecal type, the microbial diversity and the predictive functional modules of microbial community differed significantly after bowel preparation. In addition, blood biochemical markers presented somewhat associated with fecal type. Therefore, our results might provide some insights as to how knowledge of the microbial community could be used to promote health through personalized clinical treatment. Electronic supplementary material The online version of this article (10.1186/s12864-018-5285-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Hui-Mei Chen
- Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, 300, Taiwan
| | - Chung-Chu Chen
- Division of Hepatology and Gastroenterology, Department of Internal Medicine, MacKay Memorial Hospital, Hsinchu, 300, Taiwan.,Teaching Center of Natural Science, Minghsin University of Science and Technology, Hsinchu, 300, Taiwan
| | - Chien-Chi Chen
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan
| | - Shen-Chih Wang
- Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, 300, Taiwan.,Departmnet of Anesthesiology, Taipei Veterans General Hospital, Taipei, 112, Taiwan.,School of Medicine, National Yang Ming University, Taipei, 112, Taiwan
| | - Chun-Lin Wang
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan
| | - Chien-Hsun Huang
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan
| | - Jong-Shian Liou
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan
| | - Ta-Wei Liu
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan
| | - Hwei-Ling Peng
- Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, 300, Taiwan
| | - Feng-Mao Lin
- Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, 300, Taiwan.,Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, 300, Taiwan
| | - Chia-Yuan Liu
- Division of Gastroenterology, Department of Medicine & Department of Medical Research, MacKay Memorial Hospital, Taipei, 112, Taiwan.,Department of Medicine, MacKay Medical College, New Taipei City, 252, Taiwan
| | - Shun-Long Weng
- Department of Medicine, MacKay Medical College, New Taipei City, 252, Taiwan.,Department of Obstetrics and Gynecology, Hsinchu MacKay Memorial Hospital, Hsinchu, 300, Taiwan.,MacKay Medicine, Nursing and Management College, Taipei, 112, Taiwan
| | - Chieh-Jen Cheng
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan
| | - Yi-Fang Hung
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan
| | - Chii-Cherng Liao
- Food Industry Research and Development Institute, Hsinchu, 300, Taiwan.
| | - Hsien-Da Huang
- Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, 300, Taiwan. .,Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, 300, Taiwan. .,School of Science and Engineering, The Chinese University of Hong Kong, Guangdong Province, Shenzhen, 518172, China. .,Warshel Institute for Computational Biology, The Chinese University of Hong Kong, Guangdong Province, Shenzhen, 518172, China.
| |
Collapse
|
192
|
Le Barz M, Daniel N, Varin TV, Naimi S, Demers-Mathieu V, Pilon G, Audy J, Laurin É, Roy D, Urdaci MC, St-Gelais D, Fliss I, Marette A. In vivo screening of multiple bacterial strains identifies Lactobacillus rhamnosus Lb102 and Bifidobacterium animalis ssp. lactis Bf141 as probiotics that improve metabolic disorders in a mouse model of obesity. FASEB J 2018; 33:4921-4935. [PMID: 30596521 DOI: 10.1096/fj.201801672r] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Given the growing evidence that gut dysfunction, including changes in gut microbiota composition, plays a critical role in the development of inflammation and metabolic diseases, the identification of novel probiotic bacteria with immunometabolic properties has recently attracted more attention. Herein, bacterial strains were first isolated from dairy products and human feces and then screened in vitro for their immunomodulatory activity. Five selected strains were further analyzed in vivo, using a mouse model of diet-induced obesity. C57BL/6 mice were fed a high-fat high-sucrose diet, in combination with 1 of 3 Lactobacillus strains (Lb38, L. plantarum; L79, L. paracasei/casei; Lb102, L. rhamnosus) or Bifidobacterium strains (Bf26, Bf141, 2 different strains of B. animalis ssp. lactis species) administered for 8 wk at 109 colony-forming units/d. Whereas 3 strains showed only modest (Lb38, Bf26) or no (L79) effects, Lb102 and Bf141 reduced diet-induced obesity, visceral fat accretion, and inflammation, concomitant with improvement of glucose tolerance and insulin sensitivity. Further analysis revealed that Lb102 and Bf141 enhanced intestinal integrity markers in association with selective changes in gut microbiota composition. We have thus identified 2 new potential probiotic bacterial strains with immunometabolic properties to alleviate obesity development and associated metabolic disturbances.-Le Barz, M., Daniel, N., Varin, T. V., Naimi, S., Demers-Mathieu, V., Pilon, G., Audy, J., Laurin, E., Roy, D., Urdaci, M. C., St-Gelais, D., Fliss, I, Marette, A. In vivo screening of multiple bacterial strains identifies Lactobacillus rhamnosus Lb102 and Bifidobacterium animalis ssp. lactis Bf141 as probiotics that improve metabolic disorders in a mouse model of obesity.
Collapse
Affiliation(s)
- Mélanie Le Barz
- Department of Medicine, Faculty of Medicine, Cardiology Axis of the Québec Heart and Lung Institute Research Centre, Laval University, Québec, Canada.,Institute of Nutrition and Functional Foods, Laval University, Québec, Canada.,Unité Mixte de Recherche 5248, Laboratory of Microbiology and Applied Biochemistry, University of Bordeaux, Gradignan, France
| | - Noëmie Daniel
- Department of Medicine, Faculty of Medicine, Cardiology Axis of the Québec Heart and Lung Institute Research Centre, Laval University, Québec, Canada.,Institute of Nutrition and Functional Foods, Laval University, Québec, Canada
| | - Thibault V Varin
- Department of Medicine, Faculty of Medicine, Cardiology Axis of the Québec Heart and Lung Institute Research Centre, Laval University, Québec, Canada.,Institute of Nutrition and Functional Foods, Laval University, Québec, Canada
| | - Sabrine Naimi
- Institute of Nutrition and Functional Foods, Laval University, Québec, Canada.,Dairy Science and Technology Research Centre, Laval University, Quebec, Canada
| | - Véronique Demers-Mathieu
- Institute of Nutrition and Functional Foods, Laval University, Québec, Canada.,Dairy Science and Technology Research Centre, Laval University, Quebec, Canada.,Saint-Hyacinthe Research and Development Centre, Agriculture and Agri-Food Canada, Saint-Hyacinthe, Canada
| | - Geneviève Pilon
- Department of Medicine, Faculty of Medicine, Cardiology Axis of the Québec Heart and Lung Institute Research Centre, Laval University, Québec, Canada.,Institute of Nutrition and Functional Foods, Laval University, Québec, Canada
| | - Julie Audy
- Agropur Cooperative, Saint-Hubert, Quebec, Canada; and
| | | | - Denis Roy
- Institute of Nutrition and Functional Foods, Laval University, Québec, Canada
| | - Maria C Urdaci
- Unité Mixte de Recherche 5248, Laboratory of Microbiology and Applied Biochemistry, University of Bordeaux, Gradignan, France
| | - Daniel St-Gelais
- Institute of Nutrition and Functional Foods, Laval University, Québec, Canada.,Dairy Science and Technology Research Centre, Laval University, Quebec, Canada.,Saint-Hyacinthe Research and Development Centre, Agriculture and Agri-Food Canada, Saint-Hyacinthe, Canada
| | - Ismaïl Fliss
- Institute of Nutrition and Functional Foods, Laval University, Québec, Canada.,Dairy Science and Technology Research Centre, Laval University, Quebec, Canada
| | - André Marette
- Department of Medicine, Faculty of Medicine, Cardiology Axis of the Québec Heart and Lung Institute Research Centre, Laval University, Québec, Canada.,Institute of Nutrition and Functional Foods, Laval University, Québec, Canada
| |
Collapse
|
193
|
Smith-Ryan AE, Mock MG, Trexler ET, Hirsch KR, Blue MNM. Influence of a multistrain probiotic on body composition and mood in female occupational shift workers. Appl Physiol Nutr Metab 2018; 44:765-773. [PMID: 30566363 DOI: 10.1139/apnm-2018-0645] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
This study sought to investigate the effects of a multistrain probiotic on body composition, regional adiposity, and a series of associated metabolic health outcomes. Female health care workers employed on a rotating-shift schedule (n = 41) completed baseline anthropometric assessments; a fasted blood draw; questionnaires to assess anxiety, depression (Hospital Anxiety and Depression Scale), and fatigue (Chalder Fatigue Survey); and an exercise fatigue test. Identical post-tests occurred following 6 weeks of daily supplementation with placebo (PLA) or probiotics (2.5 × 109 CFU/g) containing 9 bacterial strains (PRO; Ecologic Barrier) combined with a prebiotic carrier matrix. PRO attenuated fat mass increases (change (Δ), 0.14 kg; confidence interval (CI) -0.46 to 0.75 kg) compared with PLA (Δ, 0.79 kg; CI 0.03-1.54 kg), whereas modest reductions in visceral adiposity resulted for both PRO and PLA. Metabolic biomarkers (total cholesterol, high-density lipoprotein, glucose, adiponectin, C-reactive protein, interleukin-6, leptin) were not influenced by either treatment (p > 0.05). Nonsignificant, but potentially clinically relevant, improvements in anxiety (Δ, -2.3 ± 2.63) and fatigue (Δ, -4.8 ± 5.5) were observed with PRO; exercise performance was unaffected. Results indicate a potential protective effect of probiotics against fat mass gain. Probiotics may alleviate anxiety and fatigue in shift-working females.
Collapse
Affiliation(s)
- Abbie E Smith-Ryan
- a Applied Physiology Laboratory, Department of Exercise and Sport Science, The University of North Carolina, Chapel Hill, NC 27599, USA.,b Human Movement Science Curriculum, Department of Allied Health Science, University of North Carolina, Chapel Hill, NC 27599, USA
| | - Meredith G Mock
- a Applied Physiology Laboratory, Department of Exercise and Sport Science, The University of North Carolina, Chapel Hill, NC 27599, USA
| | - Eric T Trexler
- a Applied Physiology Laboratory, Department of Exercise and Sport Science, The University of North Carolina, Chapel Hill, NC 27599, USA.,b Human Movement Science Curriculum, Department of Allied Health Science, University of North Carolina, Chapel Hill, NC 27599, USA
| | - Katie R Hirsch
- a Applied Physiology Laboratory, Department of Exercise and Sport Science, The University of North Carolina, Chapel Hill, NC 27599, USA.,b Human Movement Science Curriculum, Department of Allied Health Science, University of North Carolina, Chapel Hill, NC 27599, USA
| | - Malia N M Blue
- a Applied Physiology Laboratory, Department of Exercise and Sport Science, The University of North Carolina, Chapel Hill, NC 27599, USA.,b Human Movement Science Curriculum, Department of Allied Health Science, University of North Carolina, Chapel Hill, NC 27599, USA
| |
Collapse
|
194
|
Hibberd AA, Yde CC, Ziegler ML, Honoré AH, Saarinen MT, Lahtinen S, Stahl B, Jensen HM, Stenman LK. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Benef Microbes 2018; 10:121-135. [PMID: 30525950 DOI: 10.3920/bm2018.0028] [Citation(s) in RCA: 98] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The gut microbiota contributes to host energy metabolism, and altered gut microbiota has been associated with obesity-related metabolic disorders. We previously reported that a probiotic alone or together with a prebiotic controls body fat mass in healthy overweight or obese individuals in a randomised, double-blind, placebo controlled clinical study (ClinicalTrials.gov NCT01978691). We now aimed to investigate whether changes in the gut microbiota may be associated with the observed clinical benefits. Faecal and plasma samples were obtained from a protocol compliant subset (n=134) of participants from a larger clinical study where participants were randomised (1:1:1:1) into four groups: (1) placebo, 12 g/d microcrystalline cellulose; (2) Litesse® Ultra™ polydextrose (LU), 12 g/day; (3) Bifidobacterium animalis subsp. lactis 420™ (B420), 1010 cfu/d in 12 g microcrystalline cellulose; (4) LU+B420, 1010 cfu/d of B420 in 12 g/d LU for 6 months of intervention. The faecal microbiota composition and metabolites were assessed as exploratory outcomes at baseline, 2, 4, 6 months, and +1 month post-intervention and correlated to obesity-related clinical outcomes. Lactobacillus and Akkermansia were more abundant with B420 at the end of the intervention. LU+B420 increased Akkermansia, Christensenellaceae and Methanobrevibacter, while Paraprevotella was reduced. Christensenellaceae was consistently increased in the LU and LU+B420 groups across the intervention time points, and correlated negatively to waist-hip ratio and energy intake at baseline, and waist-area body fat mass after 6 months treatment with LU+B420. Functional metagenome predictions indicated alterations in pathways related to cellular processes and metabolism. Plasma bile acids glycocholic acid, glycoursodeoxycholic acid, and taurohyodeoxycholic acid and tauroursodeoxycholic acid were reduced in LU+B420 compared to Placebo. Consumption of B420 and its combination with LU resulted in alterations of the gut microbiota and its metabolism, and may support improved gut barrier function and obesity-related markers.
Collapse
Affiliation(s)
- A A Hibberd
- 1 Genomics and Microbiome Science, DuPont Nutrition & Health, 4300 Duncan Avenue, Saint Louis, MO 63110, USA
| | - C C Yde
- 2 DuPont Nutrition Biosciences ApS, Edwin Rahrsvej 38, 8220 Brabrand, Aarhus, Denmark.,3 Department of Food Science, Aarhus University, Kirstinebjergvej 10, 5792 Aarslev, Denmark
| | - M L Ziegler
- 4 DuPont Nutrition & Health, 3329 Agriculture Drive, Madison, WI 53716, USA
| | - A H Honoré
- 2 DuPont Nutrition Biosciences ApS, Edwin Rahrsvej 38, 8220 Brabrand, Aarhus, Denmark
| | - M T Saarinen
- 5 Global Health and Nutrition Science, DuPont Nutrition & Health, Sokeritehtaantie 20, 02460 Kantvik, Finland
| | - S Lahtinen
- 5 Global Health and Nutrition Science, DuPont Nutrition & Health, Sokeritehtaantie 20, 02460 Kantvik, Finland
| | - B Stahl
- 4 DuPont Nutrition & Health, 3329 Agriculture Drive, Madison, WI 53716, USA
| | - H M Jensen
- 2 DuPont Nutrition Biosciences ApS, Edwin Rahrsvej 38, 8220 Brabrand, Aarhus, Denmark
| | - L K Stenman
- 5 Global Health and Nutrition Science, DuPont Nutrition & Health, Sokeritehtaantie 20, 02460 Kantvik, Finland
| |
Collapse
|
195
|
Uemura M, Hayashi F, Ishioka K, Ihara K, Yasuda K, Okazaki K, Omata J, Suzutani T, Hirakawa Y, Chiang C, Aoyama A, Ohira T. Obesity and mental health improvement following nutritional education focusing on gut microbiota composition in Japanese women: a randomised controlled trial. Eur J Nutr 2018; 58:3291-3302. [PMID: 30523432 DOI: 10.1007/s00394-018-1873-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2018] [Accepted: 12/01/2018] [Indexed: 12/11/2022]
Abstract
PURPOSE Gut microbiota composition was supposedly related to obesity and psychological factors. We examined the effects of a nutritional education intervention focusing on gut microbiota composition on obesity and psychological factors among obese women. METHODS Forty-four obese Japanese women aged 40 or older were randomly assigned to either an intervention group (n = 22) or control group (n = 22). The intervention consisted of a 20-min dietary lecture and a 10-min counselling session by registered dieticians, every 2 weeks for eight consecutive weeks. Body weight, height, waist circumference, food frequency, and gut microbiota composition were measured, and self-rated health and psychological factors were scored before and after the intervention. RESULTS All participants completed the 8 week program. After the intervention, dietary fibre intake (p < 0.01), frequency of vegetable consumption (p = 0.020), and frequency of milk and milk product consumption (p < 0.01) increased significantly in the intervention group compared with the control group. Body weight and body mass index (BMI; p < 0.001), waist circumference (p < 0.01), and the depression scale score (p < 0.01) decreased significantly, while significant improvements were found in self-rated health (p = 0.045) and microbiome diversity (p < 0.01). CONCLUSION Nutritional education focusing on gut microbiota composition may improve obesity and psychological factors in obese women.
Collapse
Affiliation(s)
- Mayu Uemura
- Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan. .,Department of Epidemiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
| | - Fumikazu Hayashi
- Department of Epidemiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.,Radiation Medical Science Centre for the Fukushima Health Management Survey, Fukushima Medical University, Fukushima, Japan
| | - Ken Ishioka
- Department of Microbiology, School of Medicine, Fukushima Medical University, Fukushima, Japan
| | - Kunio Ihara
- Nagoya University Centre for Gene Research, Nagoya, Japan
| | | | - Kanako Okazaki
- Radiation Medical Science Centre for the Fukushima Health Management Survey, Fukushima Medical University, Fukushima, Japan
| | - Junichi Omata
- Preparing Section for New Faculty of Medical Science/Anatomy, Fukushima Medical University, Fukushima, Japan
| | - Tatsuo Suzutani
- Department of Microbiology, School of Medicine, Fukushima Medical University, Fukushima, Japan
| | - Yoshihisa Hirakawa
- Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Chifa Chiang
- Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Atsuko Aoyama
- Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Tetsuya Ohira
- Department of Epidemiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.,Radiation Medical Science Centre for the Fukushima Health Management Survey, Fukushima Medical University, Fukushima, Japan
| |
Collapse
|
196
|
Niibo M, Shirouchi B, Umegatani M, Morita Y, Ogawa A, Sakai F, Kadooka Y, Sato M. Probiotic Lactobacillus gasseri SBT2055 improves insulin secretion in a diabetic rat model. J Dairy Sci 2018; 102:997-1006. [PMID: 30471910 DOI: 10.3168/jds.2018-15203] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Accepted: 09/18/2018] [Indexed: 01/16/2023]
Abstract
The probiotic Lactobacillus gasseri SBT2055 (LG2055) has a protective effect against metabolic syndrome in rats and humans. Metabolic syndrome increases the risk of type 2 diabetes mellitus. In this study, Goto-Kakizaki rats were used as a diabetic model and fed diets containing LG2055-fermented or nonfermented skim milk for 4 wk. Indices of diabetes such as blood glucose levels, serum glucagon levels, plasma levels of insulin, C-peptide, and glucagon-like peptide-1, tissue glycogen contents, and pancreatic mRNA levels were measured. The plasma C-peptide levels and pancreatic mRNA levels of insulin genes (Ins1 and Ins2) and Pdx1 (a transcriptional factor of insulin genes) were increased in LG2055 diet-fed rats. The increase in insulin secretion corresponded to an improvement in serum and pancreatic inflammatory status, associated with decreases in serum levels of serum amyloid P and pancreatic levels of granulocyte colony-stimulating factor. Insulin resistance in Goto-Kakizaki rats was ameliorated by increased glycogen storage in the liver and quadriceps femoris muscles and decreased serum free fatty acid levels. This improvement may be related to the increased cecal production of short-chain fatty acids. In conclusion, dietary LG2055 improved insulin secretion in diabetic rats by improving the inflammatory status in the pancreas and serum.
Collapse
Affiliation(s)
- M Niibo
- Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan
| | - B Shirouchi
- Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan
| | - M Umegatani
- Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan
| | - Y Morita
- Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan
| | - A Ogawa
- Milk Science Research Institute, Megmilk Snow Brand Co., Ltd., 1-1-2 Minamidai, Kawagoe, Saitama 350-1165, Japan
| | - F Sakai
- Milk Science Research Institute, Megmilk Snow Brand Co., Ltd., 1-1-2 Minamidai, Kawagoe, Saitama 350-1165, Japan
| | - Y Kadooka
- Milk Science Research Institute, Megmilk Snow Brand Co., Ltd., 1-1-2 Minamidai, Kawagoe, Saitama 350-1165, Japan
| | - M Sato
- Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.
| |
Collapse
|
197
|
Jones RB, Alderete TL, Martin AA, Geary BA, Hwang DH, Palmer SL, Goran MI. Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial. Pediatr Obes 2018; 13:705-714. [PMID: 29493105 PMCID: PMC6113106 DOI: 10.1111/ijpo.12273] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2017] [Revised: 01/08/2018] [Accepted: 01/19/2018] [Indexed: 12/15/2022]
Abstract
BACKGROUND Numerous studies have shown that there are links between obesity, liver fat and the gut microbiome. However, there are mixed results on whether probiotics could impact the gut microbiome and/or help to decrease liver fat and obesity outcomes. OBJECTIVE This study aimed to determine whether a probiotic supplement (VSL#3® ) intervention altered gut microbiota and/or gut hormones associated with appetite regulation. The secondary aim of this study was to determine whether VSL#3® altered body composition and liver fat and fibrosis. METHODS We conducted a double-blind, randomized placebo-controlled trial in 19 obese Latino adolescents. The intervention consisted of three packets per day of VSL#3® or a matched placebo for 16 weeks. Pre-intervention and post-intervention measures included gut microbial abundance, gut appetite regulating hormones, anthropometrics, body composition, liver fat and liver fibrosis. We conducted linear models to determine whether there were any significant differences in the changes in these outcomes following VSL#3® intervention. RESULTS Compared with placebo, adolescents that received VSL#3 had significant increases in total adiposity (%) (+1.7 ± 0.6 vs. -1.3 ± 0.5, p < 0.01) and trunk adiposity (%) (+3.3 ± 0.8 vs. -1.8 ± 0.8, p < 0.01) with no significant effects on liver fat/fibrosis, insulin/glucose, gut microbial abundances or gut hormones. CONCLUSION VSL#3 supplementation may lead to increased adiposity in obese Latino adolescents with no significant detectable changes in gut microbiota, gut appetite-regulating hormones, liver fat and fibrosis and dietary intake. However, it is important to note that recruitment efforts were terminated early and the sample size fell short of what was planned for this trial.
Collapse
Affiliation(s)
- Roshonda B Jones
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA
| | - Tanya L Alderete
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA
| | - Ashley A Martin
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA
| | - Bree A Geary
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA
| | - Darryl H Hwang
- Department of Radiology, University of Southern California, Los Angeles, CA
| | - Suzanne L Palmer
- Department of Radiology, University of Southern California, Los Angeles, CA
| | - Michael I Goran
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA
| |
Collapse
|
198
|
Peng TR, Wu TW, Chao YC. Effect of Probiotics on the Glucose Levels of Pregnant Women: A Meta-Analysis of Randomized Controlled Trials. ACTA ACUST UNITED AC 2018; 54:medicina54050077. [PMID: 30388861 PMCID: PMC6262566 DOI: 10.3390/medicina54050077] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 10/19/2018] [Accepted: 10/30/2018] [Indexed: 12/27/2022]
Abstract
Background: Gestational diabetes mellitus (GDM) is a condition, in which women develop high blood sugar levels during pregnancy without having diabetes. Evidence on the effects of probiotics on the blood glucose levels of women with GDM is inconsistent. Objective: The present study aimed to investigate the effects of probiotics on the blood glucose levels of pregnant women. Methods: Online databases, such as PubMed, Cochrane, and Excerpta Medica Database (EMBASE) were searched for randomized controlled trials (RCTs) published before July 2018. Trials had to meet the inclusion criteria of our study. Methodological quality and risk bias were independently assessed by two reviewers. Data were pooled using a random effects model and were expressed as the mean difference (MD) and 95% confidence interval (CI). Heterogeneity was evaluated and quantified as I2. Results: In total, 12 RCTs were included in this study. Studies have shown that the use of probiotics significantly reduced the fasting blood glucose (FBG) level (MD: −0.10 mmol/L; 95% CI: −0.19, −0.02), insulin concentration (MD: −2.24 μIU/mL; 95% CI: −3.69, −0.79), Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score (MD: −0.47; 95% CI: −0.74, −0.21), and Homeostasis model of assessment-estimated β cell function (HOMA-B) score (MD: −20.23; 95% CI: −31.98, −8.49) of pregnant women. In a subgroup analysis, whether the blood glucose-lowering effect of probiotics influenced the diagnosis of pregnant women with GDM was assessed. The results showed that probiotics had significantly reduced the fasting blood glucose (FBG) level (MD: −0.10 mmol/L; 95% CI: −0.17, −0.04) and HOMA-IR score (MD: −0.37; 95% CI: −0.72, −0.02) of pregnant women who were not diagnosed with GDM. Conclusion: Probiotics reduce the blood glucose level of pregnant women, especially without GDM diagnosis. However, further research using RCTs must be conducted to validate the results of the present study.
Collapse
Affiliation(s)
- Tzu-Rong Peng
- Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
| | - Ta-Wei Wu
- Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.
| | - You-Chen Chao
- Division of Gastroenterology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
- School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
| |
Collapse
|
199
|
Is It Time to Use Probiotics to Prevent or Treat Obesity? Nutrients 2018; 10:nu10111613. [PMID: 30388851 PMCID: PMC6266556 DOI: 10.3390/nu10111613] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 10/30/2018] [Accepted: 10/31/2018] [Indexed: 12/11/2022] Open
Abstract
In recent years, attention has been given to the role potentially played by gut microbiota in the development of obesity. Several studies have shown that in individuals with obesity, the gut microbiota composition can be significantly different from that of lean individuals, that faecal bacteria can exert a fundamental role in modulating energy metabolism, and that modifications of gut microbiota composition can be associated with increases or reductions of body weight and body mass index. Based on this evidence, manipulation of the gut microbiota with probiotics has been considered a possible method to prevent and treat obesity. However, despite a great amount of data, the use of probiotics to prevent and treat obesity and related problems remains debated. Studies have found that the probiotic effect on body weight and metabolism is strain specific and that only some of the species included in the Lactobacillus and Bifidobacterium genera are effective, whereas the use of other strains can be deleterious. However, the dosage, duration of administration, and long-term effects of probiotics administration to prevent overweight and obesity are not known. Further studies are needed before probiotics can be rationally prescribed for the prevention or treatment of obesity. Control of the diet and environmental and life-style factors that favour obesity development remain the best solution to problems related to weight gain.
Collapse
|
200
|
Wang H, Zhang X, Wang S, Li H, Lu Z, Shi J, Xu Z. Mannan-oligosaccharide modulates the obesity and gut microbiota in high-fat diet-fed mice. Food Funct 2018; 9:3916-3929. [PMID: 29974116 DOI: 10.1039/c8fo00209f] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The gut microbiota is considered to be associated with high-fat diet (HFD)-induced obesity and metabolic syndrome (MS). Mannan-oligosaccharide (MOS) is widely used as a natural additive, and its effect on promoting fat metabolism has been reported. Here, we performed a 11-week study on C57BL/6J mice fed a high-fat diet (HFD) with/without MOS supplementation, and the results showed that MOS could attenuate high-fat diet induced metabolic syndrome, including slower body weight gain, lowered serum lipids and reduced insulin resistance. Next generation sequencing (NGS) of the gut microbiota indicated that MOS modulated the overall structure of the gut microbiome, which was highly correlated with MS parameters. Specifically, the intake of MOS decreased the Firmicutes/Bacteroidetes ratio and could reverse the changes in the relative abundance of several species caused by HFD, including Akkermansia muciniphila, Bacteroides acidifaciens, Lactobacillus gasseri and Bifidobacterium pseudolongum. Thus, MOS has the potential to be used as a new prebiotic for regulating the gut microbiota and helping in attenuating metabolic disorders.
Collapse
Affiliation(s)
- Hongshan Wang
- School of Pharmaceutical Science, Jiangnan University, 1800 Lihu Avenue, Wuxi 214122, China
| | | | | | | | | | | | | |
Collapse
|